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PREFACE
The dissertation that follows is the result of my training as a graduate student in
the laboratory of Dr. Pablo A. Ortiz at Hypertension and Vascular Research Division,
Henry Ford Hospital, Detroit. Since I had some prior research experience with total
internal reflection fluorescence (TIRF) microscopy, during the first 1.5 years, we
developed a method for real-time monitoring of Na+/K+/2Cl- co-transporter (NKCC2)
endocytosis by TIRF microscopy in Mardin Darby Canine Kidney (MDCK) cells and in
thick ascending limb (TAL) primary cultured cells. However, the focus of research in the
lab at the time was to elucidate novel protein-protein interactions of NKCC2 that
regulate NKCC2 apical trafficking. Thus, while I was preparing to submit the abovementioned work for publication to American Journal of Physiology as the first author, I
had started working on my main dissertation project to determine the role of ALMS1 in
NKCC2 endocytosis, NaCl reabsorption and blood pressure. The work that led to this
dissertation was performed by a previous colleague in the lab who had identified
ALMS1 as one of the interacting partners with the carboxyl-terminus of NKCC2, a
domain important for NKCC2 endocytosis. NKCC2 endocytosis is a critical mechanism
to regulate NaCl reabsorption by the kidney, which plays a vital role in the regulation of
arterial pressure.
In the years preceding the preparation of this dissertation, I completed another
manuscript as first author corresponding to my main project which I submitted to my
mentor for ultimate publication in Journal of Clinical Investigation. While performing my
main research, I became interested in characterizing the ALMS1 rat knockout (KO)
model for metabolic, cardiovascular and renal function which became the focus of my
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third first author manuscript to be submitted to American Journal of Physiology. In this
dissertation, I demonstrate that ALMS1 interacts with NKCC2 and stimulates NKCC2
endocytosis and maintains normal NKCC2 surface expression and NKCC2-mediated
NaCl reabsorption by the TAL, thereby maintaining normal blood pressure. Further, I
show that deletion of ALMS1 in rats leads to the development of age-dependent
metabolic syndrome. All data used in this thesis are either already published or are in
the process of being published.
Data such as characterization of endothelial, cardiovascular function in ALMS1
knockout rats will be included in a separate manuscript where I am a contributing
author. I performed GST-pull down assays with carboxyl-terminus ALMS1 in rat TAL
lysates and pulled down a number of proteins which if pursued in the future per Dr.
Ortiz, will guarantee my name as a contributing author in the respective manuscript/s. I
was also involved in providing scientific input and maintaining an ALMS1 KO rat colony
for a graduate student in the lab: Keyona N. King-Medina for three years and hence will
be a contributing author in both her ALMS1-related manuscripts. I maintained ALMS1
mutant and floxed mice colonies for three years and hence will be a contributing author
in the corresponding manuscripts. In summary, my work as a graduate student in Dr.
Ortiz’s lab has contributed to several manuscripts published, submitted or awaiting
submission to peer-reviewed journals for publication.
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CHAPTER 1 - BACKGROUND AND GENERAL HYPOTHESIS
Anatomy of the kidney
Nephrons are the structural and functional building blocks of the kidney
(Figure1). Each nephron consists of a glomerulus through which blood is filtered into
the tubular space called the Bowman’s capsule. The filtrate then passes along the
various segments of the tubule, where it is modified in composition and ultimately
excreted as urine. Various segments of the nephron have different absorptive and

Figure 1: Diagrammatic representation of anatomy of the kidney and the nephron

secretory properties. Excretion of waste metabolites, ions and osmolytes are regulated
by the kidneys and thus is an important determinant of blood pH, osmolality, ion and
water composition.

Additionally, renal tubular segments secrete several vasoactive

substances and therefore allow a coordinated regulation of fluid volume in the
extracellular compartments, a determinant of blood pressure.
One of the segments is the loop of Henle, which extends deep into the renal
medulla. The most distal part of the loop of Henle is the thick ascending limb (TAL),
which is divided into medullary and cortical regions.
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Role of NKCC2 in NaCl reabsorption by the thick ascending limb
The TAL reabsorbs about 25 - 30% of the NaCl load filtered by the glomerulus.
TAL reabsorbs Na+, Cl-, Mg2+, Ca2+ ions while remaining impermeable to the movement
of water. This results in a hyperosmotic interstitium via a counter current multiplier
mechanism that generates osmotic force for water reabsorption at the collecting duct.
Thus TAL plays a vital role in regulating water and ion reabsorption in the kidney
thereby influencing, urine concentration and the regulation of arterial pressure.
Figure 2 shows a currently accepted model for NaCl reabsorption in the TAL.
Epithelial cells that line the TAL have apical-basolateral polarity.
Figure
2: Representation of
NaCl
reabsorption by the thick ascending limb

On the apical surface, Na+/K+/2Cl- co-transporter (NKCC2) and Na-H exchanger
(NHE3) (not shown) [1,2,11,12] reabsorb Na+, K+ and Cl- ions from the lumen by utilizing
the electrochemical gradient [3-5] generated by the sodium-potassium pump (Na+-K+
ATPase) in the basolateral membrane. Na+ exits the cell at the basolateral side through
the Na+-K+ ATPase while the Cl- leaves through the Cl- channels and K+/2Cl- co-
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transporters [5,6,7].
K+ ions are recycled back into the lumen via the renal outer medullary potassium
channel (ROMK) [8], thereby creating a positive luminal electric potential that drives
Na+, Ca2+, Mg2+ absorption via the paracellular pathway [9,10].
Control of blood pressure: Role of NKCC2
Bartter syndrome type I [13-19] is characterized by polyuria, inability to
concentrate urine and hypotension [20-22] and is caused by loss of function mutations
in NKCC2. Mice models with genetic deletion of NKCC2 recapitulate Bartter syndrome
type I phenotype [23], associated with severe volume depletion.

Two independent

groups [24,25] have shown that mutations in NKCC2 decrease NKCC2-mediated NaCl
reabsorption and blood pressure in humans. Conversely, enhanced NKCC2-mediated
NaCl reabsorption is associated with salt-sensitive hypertension in animal models [2529] and in humans [30,31].

NKCC2 activity is inhibited by loop diuretics such as

bumetanide and it is used clinically for the treatment of hypertension. Thus, NKCC2mediated NaCl absorption by the TAL is crucial in regulation of blood pressure [30,32].
Regulation of NKCC2 by protein trafficking
NKCC2-mediated NaCl reabsorption is regulated by 1) phosphorylation at
threonine (96/101) by STE20- and SPS1-related proline and alanine-rich kinases
(SPAK) and oxidative stress-responsive kinase 1 (OSR1) [49,96-98] and at Ser(126)
site by PKA [99], 2) protein-protein interactions [49,100-102] and 3) protein trafficking
determining NKCC2 apical abundance [29,33,37,38]. While the regulation of NKCC2
via phosphorylation has been well studied, very little is known about mechanisms and
protein-protein interactions which regulate NKCC2 apical trafficking.

While most

NKCC2 is located sub-apically as visualized by electron microscopy [34], our laboratory
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previously showed that at a steady-state, only a small fraction (~5%) of the total NKCC2
is targeted to the apical surface of the TAL cells [35]. Steady-state surface NKCC2
levels are maintained by a balance between various protein trafficking modalities such
as exocytic delivery [36], endocytosis and recycling [37,38], together determining
NKCC2 activity (Figure 3).

Our lab previously showed that blocking NKCC2

endocytosis leads to increased NKCC2 levels at the apical surface and increased
NKCC2-mediated NaCl absorption in the TAL [37,38]. Additionally, surface NKCC2 was

Figure 3: Trafficking pathways of NKCC2 in the thick ascending limb.

found to be significantly higher in a rat model of salt-sensitive hypertension [29]. These
observations demonstrate the important relationship between regulation of NKCC2
abundance at the apical membrane by NKCC2 endocytosis and NKCC2-mediated NaCl
reabsorption by the TAL. This also highlights the importance of NKCC2 endocytosis as
a mechanism to regulate renal function and blood pressure.

5
Single molecule tagging method to measure NKCC2 endocytosis in real time
Given the significance of NKCC2 endocytosis in regulating NKCC2 activity, the
dynamic process of this mechanism is poorly understood partly due to lack of methods
to study endocytosis. Biochemical surface biotinylation of apical proteins with NHS-SS
biotin [37,38] has been used to measure the rate of NKCC2 endocytosis. However
there are several disadvantages in this biochemical technique because it is limited in its
time resolution and cannot capture the dynamic process of endocytosis in real time [39].
Optical methods such as total internal reflection fluorescence (TIRF) microscopy have
been developed that permit imaging trafficking events at the plasma membrane. TIRF
microscopy generates an evanescent field of illumination penetrating to about ~200 nm
into the cell thereby allowing direct imaging of fluorescent molecules at or near the
plasma membrane, and thus may be well suited for imaging individual endocytic events
in real time [40]. TIRF microscopy has been previously used to study trafficking of
clathrin-coated vesicles and many membrane proteins in non-polarized cells [41- 43, 45,
46]. In polarized cells, TIRF microscopy has been used to image basolateral membrane
trafficking dynamics of several proteins [47]. Imaging trafficking events at the apical
membrane has been challenging due to technical limitations of the TIRF configuration,
which requires a glass-water interface to generate the evanescent field. However in the
recent years, there have been successful attempts to adapt this technique to image
proteins in recycling endosomes which are in close proximity to the apical membrane
[48,46]. Therefore TIRF imaging with site-specific fluorescent labeling of NKCC2 may
allow monitoring of NKCC2 endocytosis with high signal to noise ratio and good time
resolution in Mardin Darby Canine Kidney (MDCK) cells and TAL primary cultured cells.

6
Studying protein-protein interactions that play a role in regulating NKCC2
endocytosis
Despite the importance of NKCC2 endocytic pathway and development of novel
methods to study the dynamic process, the molecular mechanisms that regulate
NKCC2 endocytosis are not clear. Protein-protein interactions with NKCC2 as in the
case of myelin and lymphocyte-associated protein (MAL/VIP17) has been described to
regulate NKCC2 endocytosis [49] by interacting with a 71 amino acid domain in the
carboxyl-terminus of NKCC2 (C2-NKCC2), shown to be important for apical targeting of
NKCC2 [81]. Targeted proteomics using glutathione-S-transferase (GST) fusion protein
with C2-NKCC2 as bait in the TAL is a promising method [44] to identify and
characterize new C2-NKCC2 interacting partners and will allow characterization of novel
proteins that play a role in NKCC2 endocytosis, regulation of blood pressure and renal
function. In a GST pull-down assay in rat TAL, we identified (Alström syndrome 1
protein) ALMS1 as a novel interacting partner of C2-NKCC2.
Role of ALMS1 in hypertension, renal and metabolic function
ALMS1 is a protein initially associated to Alström syndrome. This is a human
disorder characterized by hypertension, obesity, insulin resistance, kidney dysfunction
and chronic kidney disease.

Renal impairment in these patients include reduced

glomerular filtration rate (GFR) and albuminuria. Renal function deteriorates with age
and end-stage renal disease is a common cause of death in these patients [50-53].
Two independent genome-wide association studies discovered single nucleotide
polymorphisms in ALMS1 locus associated with GFR and chronic kidney disease [6265]. Hypertension is a common risk factor for chronic kidney disease (CKD) [54, 55].
ALMS1 gene was linked to hypertension status in a multipoint linkage analysis in
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primary sibling samples of African American, Caucasian and Mexican population. In this
population analysis, seven single nucleotide polymorphisms in ALMS1 were associated
with hypertension and increased pulse pressure [56].

Quantitative trait loci (QTL)

associated with blood pressure and salt-sensitive hypertension were mapped to ALMS1
locus [57-61]. However, the mechanism involved in regulation of Na+ handling in the
kidney and salt-sensitive hypertension by ALMS1 is unknown.
Role of ALMS1 in protein trafficking
ALMS1 was originally shown to be present in the basal body of the cilia, yet
fibroblasts from human Alström syndrome patients have normal cilia but had defects in
trafficking of transferrin [66]. Therefore, the pathology observed in these patients may
be due to defects in intracellular trafficking [51,67,68]. In ALMS1 mutant mice, the
apical protein rhodopsin in the retina is mislocalized, suggesting a role for ALMS1 in
intracellular trafficking in the retina [67]. Loss of ALMS1 caused accumulation of notch
receptors in the late endosomes but did not affect recycling [68], suggesting a role in
endosome trafficking. ALMS1 mutant mice displayed altered intracellular localization of
glucose transporter-4 (GLUT4) and decreased insulin-stimulated trafficking of GLUT4 to
the plasma membrane in adipocytes [69]. Proteins such as alpha-actinin1/4 (ACTN1/4),
Myosin Vb (MYO5B), Rad50 interactor 1 (RINT1) play a role in endocytosis [66,70-73]
and interact with ALMS1. We hypothesize that ALMS1 acts as a scaffolding protein
between the cytoskeleton and membrane proteins during endocytosis.
Protein-protein interaction as a possible mechanism for ALMS1-mediated
endocytosis of NKCC2
The genetic association of obesity, salt-sensitive hypertension with ALMS1, its
cellular role in trafficking of membrane protein [69] and its interaction with proteins in the
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endocytic pathway [66] are well described.

In this dissertation, we tested whether

ALMS1 interacts with NKCC2 as a possible mechanism that stimulates NKCC2
endocytosis and decreases surface NKCC2 abundance, NKCC2-mediated NaCl
reabsorption by the TAL, thereby maintaining normal blood pressure. We also tested
the effect of deletion of ALMS1 in the development of metabolic dysfunction in rats.
General hypothesis and project aims
In this work we developed a method to measure NKCC2 endocytosis in real time
by TIRF microscopy and tested the general hypothesis that ALMS1 interacts with
NKCC2 in the thick ascending limb to stimulate NKCC2 endocytosis, decrease NaCl
reabsorption, and thereby maintains normal blood pressure. We also tested the role of
ALMS1 in maintaining normal metabolic function in rats. We addressed this hypothesis
in five aims that follow.
Aim 1: Hypothesis: Site-specific labeling allows visualization of apical NKCC2 by
Total internal reflection fluorescence (TIRF) microscopy in polarized MDCK and
TAL cells
We will transduce biotin acceptor domain (BAD) tagged NKCC2 to perform site
specific biotinylation of surface NKCC2 mediated by Escherichia coli biotin ligase (BirA).
Fluorescent labeling of biotinylated NKCC2 will be performed for imaging surface
NKCC2 by total internal reflection fluorescence (TIRF) microscopy.
Aim 2: Hypothesis: Total internal reflection fluorescence (TIRF) microscopy
allows monitoring of NKCC2 endocytosis in polarized MDCK and TAL cells in real
time
We will measure intensities of surface NKCC2 puncta for monitoring endocytic
events signified by exponential decrease in the intensity of an individual punctum. The
rate of NKCC2 endocytosis will be calculated by measuring the rate of disappearance of
surface NKCC2 puncta on the TIRF field.
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Aim 3: ALMS1 interacts with NKCC2 and stimulates NKCC2 endocytosis thereby
decreasing steady-state surface NKCC2 expression
First, we will confirm that ALMS1 is a part of a complex with NKCC2 in TALs.
Then we will define the region of ALMS1 that interacts with NKCC2. We will inhibit
ALMS1 expression in vivo in rat TALs by a) gene silencing via short hairpin RNA
(shRNA), b) ALMS1 genetic deletion in rats. We will then measure steady-state surface
NKCC2 and rate of NKCC2 endocytosis in TALs.
Aim 4: ALMS1 decreases NKCC2-mediated NaCl reabsorption by the TAL, thereby
plays a role in salt sensitive hypertension
We will inhibit ALMS1 expression in vivo by genetic deletion of ALMS1 in rats.
We will then measure bumetanide-induced water and NaCl excretion and systolic blood
pressure on normal salt and water diet. We will measure salt sensitivity by measuring
systolic blood pressure response to increasing salt in drinking water.
Aim 5: Deletion of ALMS1 causes sex-based differences in development of agedependent metabolic syndrome in rats
We will inhibit ALMS1 expression by genetic deletion of ALMS1 in rats. We will
measure body weight, abdominal fat pad weight, average daily food intake, random
blood glucose, fasting blood glucose, plasma insulin and leptin, serum triglyceride,
cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL) levels and
systolic blood pressures in 6-12 week and 16-18 week old male and female rats.
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CHAPTER 2 - REAL TIME MONITORING OF NKCC2 ENDOCYTOSIS BY TOTAL
INTERNAL REFLECTION FLUORESCENCE MICROSCOPY
(This chapter contains previously published material. See Appendix C)
Introduction
The abundance of NKCC2 at the apical membrane of TAL cells is determined by
a balance between exocytic delivery, recycling, and endocytosis. Biochemical surface
biotinylation allows measurement of these trafficking modalities such as NKCC2
endocytosis. However, this method has low time resolution and does not allow imaging
of the dynamic process of endocytosis [39,40]. In this chapter we tested whether total
internal reflection fluorescence (TIRF) microscopy imaging of labeled NKCC2 would
allow monitoring of NKCC2 endocytosis in polarized Mardin Darby Canine Kidney
(MDCK) and TAL primary cultured cells. We tested this in two aims by transducing a
NKCC2 construct containing a biotin acceptor domain (BAD) sequence between the 5th
and 6th trans-membrane domains in MDCK and TAL cells.

This would allow

biochemical and/or metabolic NKCC2-specific biotinylation. Subsequent labeling with a
fluorophore was performed for TIRF live cell imaging and visualizing individual
endocytic events in real-time.
Aim 1: Hypothesis: Site-specific labeling allows visualization of apical NKCC2 by
Total internal reflection fluorescence (TIRF) microscopy in polarized MDCK and
TAL cells
Rationale
Site-specific biotinylation of cell surface proteins is achieved by tagging proteins
with a biotin acceptor domain (BAD) sequence, catalyzed by Escherichia coli biotin
ligase (BirA) to add biotin moieties to the lysine residue of the sequence [74-77]. This is
an efficient method to tag and image apical proteins in mammalian cells [78,79]. Optical

11
methods such as total internal reflection fluorescence (TIRF) microscopy which
generate an evanescent field of illumination, allow direct imaging of fluorescent
molecules at or near the plasma membrane with high signal-to-noise ratio [40]. Here
we tested whether NKCC2- specific biotinylation at the apical surface by exogenously
added or co-expressed BirA allows imaging of surface NKCC2 by TIRF microscopy.
Results
Heterologous NKCC2 can be expressed in polarized MDCK cells
Full-length NKCC2 has been successfully expressed in non-polarized cells such
as opossum kidney cells [80] while only a few investigators have succeeded in
expressing it in polarized cells [81].

We expressed full-length NKCC2 construct in

polarized epithelial cells, and tested whether N-terminus eGFP-tagged NKCC2 is
expressed and targeted to apical membrane in polarized MDCK cells. For this, MDCK
cells grown to confluence on collagen-coated permeable support transwells were
transduced with eGFP-NKCC2 adenoviruses and then co-labeled for NKCC2 and tight
junction protein zonula occludens-1 (ZO-1).
Figure 4A shows a representative image of MDCK cells in which eGFP-NKCC2
(in green) was observed in the same plane as ZO-1 (in red). In order to verify lack of
basolateral targeting of eGFP-NKCC2, eGFP-NKCC2 transduced MDCK cells were
labeled with antibodies that bind surface NKCC2 (directed to the extracellular loop
between TM5-TM6) on both the apical and basolateral compartment of the transwell in
addition to apical tight junction protein ZO1. X-Y and Y-Z confocal reconstruction of
polarized MDCK cells show that NKCC2 was only located in the apical surface in the
same plane as ZO-1, while no labeling was observed in the lateral or basolateral
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membranes (Figure 4B).
A

C

B

Figure 4: Apical targeting of eGFP-NKCC2 in polarized MDCK cells. A) Immunofluorescence labeling of
ZO-1 (red) and eGFP-NKCC2 (green). Scale bar = 5 µm, n = 3. B) X-Y and Y-Z confocal reconstruction of
MDCK cell monolayer immuno-labeled with surface eGFP-NKCC2 (green) and ZO-1 (red), n = 3. C)
Representative Western blot indicating presence of eGFP-NKCC2 in the apical surface protein fraction of
MDCK cells subjected to surface biotinylation, n = 4.

To confirm that eGFP-NKCC2 reached the apical surface in MDCK cells,
biotinylation of apical or basolateral surface proteins of eGFP-NKCC2 transduced
MDCK cells was performed. This was done by masking biotinylation sites either in the
apical or basolateral membranes of MDCK cells growing on trans-wells by NHS-acetate
to facilitate biotinylation of basolateral or apical proteins respectively. Expression of
eGFP-NKCC2 was observed only in the apical surface fraction but not in the basolateral
surface fraction (Figure 4C). Taken together, these data indicate correct targeting of
eGFP-NKCC2 to the apical membrane but not to the basolateral membrane in polarized
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MDCK cells.
Site-specific NKCC2 biotinylation and apical labeling for TIRF microscopy
imaging
After confirming apical targeting of NKCC2 construct in polarized MDCK cells, we
developed a method to selectively label NKCC2 at the apical surface. To selectively tag
NKCC2, a NKCC2 construct containing a Biotin Acceptor Domain (BAD) in the
extracellular loop between trans-membrane domains 5 and 6 (NKCC2-BAD) was
generated.

MDCK cells were transduced with NKCC2-BAD adenoviral construct

(Figure 5) and biochemical surface biotinylation was achieved by exogenous addition of
Figure 5: Expression of
NKCC2-BAD
on
apical
surface of MDCK cells.
Schematic representation of
expression of NKCC2-BAD on
the apical membranes of MDCK
cells. The Biotin Acceptor
Domain (BAD) inserted in the
extracellular loop between the
5th and 6th trans-membrane
domain of NKCC2.

bacterial biotin ligase BirA, biotin and ATP for 15 minutes to the apical side of the
transwell [78].

Fluorescent labeling of biotinylated apical NKCC2 was achieved by

incubating the apical surface with Alexa Fluor 488- conjugated streptavidin (Figure 6).
Figure 6: Step-wise selective
biotinylation of surface NKCC2BAD
and
labeling
with
Streptavidin Alexa Fluor 488.
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Apical membranes were then imaged by TIRF microscopy in a temperaturecontrolled chamber as shown in Figure 7. TIRF microscopy is based on the principle of
generation of an evanescent field upon laser excitation to allow fluorescence of
molecules only in the immediate vicinity (100-200 nm) of the glass coverslip [82,83]. To
maximize the apical membrane area in proximity to the glass coverslip to be visualized,
the collagen-coated membrane was gently pushed with a glass pipette.

Figure 7: Diagrammatic representation of temperature controlled chamber set up for live cell
imaging of apical membranes by TIRF microscopy.

As shown in Figure 8A, NKCC2 was observed at the apical surface of MDCK
cells.

Heterogeneous pattern of distribution of apical surface NKCC2 restricted to

discrete domains referred here as puncta (singular- punctum) was observed which
Figure 8: TIRF images of apical
membranes
of
MDCK
cells
expressing NKCC2-BAD subject to
biochemical
biotinylation.
Biotinylation performed A) with or B)
without biotin ligase (BirA) followed by
labeling with streptavidin Alexa Fluor
488, n = 3. Scale bar = 10 µm.
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appeared to be clustered (Figure 9). Clustering was demonstrated by measuring area
of individual surface NKCC2 punctum while area of individual immobilized fluorescent
biotin beads on a glass slide served as a control. To assure that only NKCC2 was
A

B

Figure 9: Clustering of NKCC2 puncta. A) Distribution of NKCC2 surface puncta area and abundance.
B) Mean area of surface NKCC2 puncta measured with Metamorph® software. Immobilized fluorescent
biotin beads on a glass slide serve as control, n = 3 (~50 puncta per slide), * p < 0.05 vs. control.

biotinylated, negative controls were performed in parallel to every experiment. MDCK
cells transduced with NKCC2-BAD were incubated in the absence of BirA but in the
presence of biotin followed by streptavidin labeling. Negative controls showed absence
of non-specific labeling in MDCK cells (Figure 8B). These data indicate that genetic
incorporation of the BAD domain to NKCC2 results in specific biotinylation of NKCC2 by
BirA at the apical surface of polarized MDCK cells for TIRF imaging.
Metabolic biotinylation yields specific labeling of NKCC2-BAD in MDCK cells
Our data indicate that surface NKCC2-BAD can be successfully biotinylated
biochemically by exogenous addition of BirA to the apical bath of the transwells.
However this method may be associated with experimental variability in tagging NKCC2
with biotin due to numerous steps involved. In addition, ATP in the reaction mixture can
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potentially cause purinoceptor activation [84,85].

In order to improve our previous

biotinylation method, we performed metabolic biotinylation of NKCC2-BAD via cotransduction of MDCK cells with a secretory form of the enzyme (ssBirA) [74,75,86,87].
The presence of the secretory signal (ss) in the BirA ensures that expressed biotin
ligase will be in contact with proteins in the trans-Golgi and the secretory pathway to
allow biotinylation of proteins with endogenous biotin eliminating the need of exogenous
addition of BirA and biotin. 24 hrs after co-transduction, cells were then cooled to 4ºC
and directly labeled with Alexa Fluor 488- conjugated streptavidin.

To assure that

NKCC2 biotinylation and labeling was specific, a negative control was included in
parallel to every experiment in which MDCK cells were transduced with only NKCC2BAD but not with ssBirA followed by streptavidin labeling. We observed apical surface
NKCC2-BAD biotinylation as indicated by surface puncta obtained by TIRF imaging
(Figure 10A). No signal was observed in the negative control which indicated specific
biotinylation and labeling of NKCC2-BAD by co-expressed ssBirA (Figure 10B). These
data indicate that metabolic biotinylation can be used as a more convenient alternative
to biochemical biotinylation for imaging apical NKCC2 by TIRF microscopy.
Figure 10: TIRF images of apical
membranes of MDCK cells expressing
NKCC2-BAD
subject
to
metabolic
biotinylation. Biotinylated performed A)
with or B) without secretory signal biotin
ligase (ssBirA) followed by labeling with
streptavidin Alexa Fluor 488, n = 3. Scale
bars = 10 µm.

Metabolic biotinylation yields specific labeling of NKCC2-BAD in TAL cells
To test whether apical NKCC2 can be specifically tagged and imaged by TIRF
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microscopy in native TALs, we generated primary cultures of rat TALs as described
[88]. Primary cultures of rat TAL cells were co-transduced with adenoviral NKCC2-BAD
and ssBirA constructs to induce metabolic biotinylation.

Figure 11A shows a

representative image of NKCC2 puncta observed at the apical surface of rat TAL
primary cultured cells after labeling with streptavidin.
Figure 11: TIRF images of apical
membrane of rat TAL cells expressing
NKCC2-BAD
subject
to
metabolic
biotinylation. Biotinylation performed A)
with or B) without secretory signal biotin
ligase (ssBirA) followed by labeling with
streptavidin Alexa Fluor 488, n = 3. Scale
bar = 10 µm.

In parallel to every experiment, negative controls were performed in which TAL
cells were transduced with only NKCC2-BAD but not with ssBirA to ensure NKCC2specific biotinylation was performed followed by labeling with Alexa Fluor 488conjugated streptavidin. As shown in Figure 11B, no labeling was observed in negative
control cells. These data indicate that NKCC2-BAD can be specifically labeled at the
apical surface of rat TAL primary cultures for imaging by TIRF microscopy.
Conclusion
We observed that transduction of NKCC2 construct containing a biotin acceptor
domain (BAD) sequence between the 5th and 6th trans-membrane domains in MDCK
and TAL cells allowed NKCC2-specific biotinylation by exogenous biotin ligase (BirA).
We also demonstrate that expression of a secretory form of BirA in TAL cells induced
metabolic biotinylation of NKCC2. Subsequent labeling with a fluorophore allowed live
cell imaging by TIRF microscopy. On the TIRF field, we observed that most apical
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NKCC2 was located within small discrete domains or clusters referred to as ‘puncta’.
Therefore we conclude that site-specific labeling of NKCC2 allows visualization of apical
NKCC2 by Total Internal Reflection Fluorescence (TIRF) microscopy in polarized MDCK
and TAL cells. The significance and in depth interpretation of all these observations will
be addressed in the discussion in Chapter 5.
Aim 2: Hypothesis: Total internal reflection fluorescence (TIRF) microscopy
allows monitoring of NKCC2 endocytosis in polarized MDCK and TAL cells in real
time
Rationale
The thick ascending limb (TAL) of the loop of Henle reabsorbs about 25 - 30% of
the NaCl filtered by the glomerulus via the apical Na+-K+-2Cl- co-transporter (NKCC2)
[37,38].

Under steady-state conditions, only a small fraction of NKCC2 (4-5%) is

present at the apical surface while the rest of the NKCC2 pool is located sub-apically
[11,34,35]. Recent studies indicate a direct relationship between the amount of NKCC2
at the apical surface with NKCC2 activity and the reabsorptive capacity of the TAL
[36,35]. The steady-state levels of NKCC2 at the apical surface are maintained by a
dynamic balance between endocytosis, exocytic delivery, and recycling [36-38,88].
However, the underlying molecular mechanisms of NKCC2 trafficking and the proteins
involved are poorly understood. This is in part due to a lack of methods to study NKCC2
trafficking.
Surface biotinylation of apical proteins with NHS-SS biotin [37,38] is used to
study NKCC2 endocytosis. However, this technique has several limitations because it
cannot capture the dynamics of endocytosis in real time [39,40]. Optical methods such
as TIRF microscopy have been developed that allow imaging of trafficking events at the
plasma membrane.

For example, TIRF microscopy has been used to study the
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dynamic process of trafficking of clathrin-coated vesicles along with many membrane
proteins in non-polarized cells [41-46]. In polarized cells, TIRF microscopy has been
used to image basolateral membrane dynamics of trafficking of several proteins [47].
Very recently, TIRF imaging has been applied to visualize apical and sub-apical
trafficking events in polarized epithelial cells [48,49].

We hypothesized that TIRF

imaging of apical NKCC2 would allow monitoring of NKCC2 endocytosis with good time
resolution.
Results
Visualization of individual NKCC2 endocytic events on apical surface of MDCK
cells in real time.
After apical NKCC2-specific tagging and imaging by TIRF microscopy in MDCK
cells, we monitored the disappearance of an individual NKCC2 punctum in real time
which is an indication of an endocytic event.

Cells were placed at 37ºC to allow

endocytosis, and images were acquired every second by TIRF microscopy. Individual
surface NKCC2 punctum was tracked by defining a region of interest as shown in
Figure 12A and its fluorescence intensity was quantified.
A

A rapid decrease in

B

Figure 12: Single NKCC2 endocytic event at the apical membrane of MDCK cells captured by TIRF
microscopy. A) Snapshots of TIRF images taken every 1 second. Individual NKCC2 punctum are
encircled in red. B) Graphical representation of fluorescence intensity of a NKCC2 punctum undergoing
internalization.
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fluorescence reaching background fluorescence intensity within a second was observed
(Figure 12B), representing a single endocytic event. Occurrence of several endocytic
events resulted in a decrease in the total number of surface NKCC2 puncta on the TIRF
field over time which was quantified with the Granularity module of Metamorph®. The
number of surface puncta was analyzed over a period of 20 minutes and 23.5 ± 6.1% of
the initial number of NKCC2 punctum were observed to disappear from the cell surface
(Figure 13). This is representative of an endocytic rate of 1.18 ± 0.16 % per minute

Figure 13: Graphical representation of change in
number of NKCC2 surface puncta over time in
MDCK cells. Under conditions of with or without 5
mM Methyl β cyclodextrin (MβCD) n = 5, * p < 0.01
vs. baseline.

under baseline conditions. To assure that the disappearance of NKCC2 puncta from
the surface was due to NKCC2 endocytosis, cells were pre-treated with 5 mM Methyl-βcyclodextrin (MβCD), a cholesterol chelating agent previously shown to completely
block NKCC2 endocytosis [38]. Treatment of MβCD completely prevented the decrease
of NKCC2 puncta from the TIRF field of view and consequently the number of surface
puncta did not change significantly over 20 minutes. The rate of NKCC2 endocytosis in
the presence of MβCD was 0.14 ± 0.06 % per minute (p < 0.01 MβCD treated vs.
untreated) (Figure 13). These data indicate that the decrease in the number of surface
NKCC2 puncta observed under baseline conditions was indeed due to NKCC2
endocytosis.

21
Studying NKCC2 endocytosis in rat TAL cells
To test whether apical surface TIRF imaging can be used to study endocytosis in
native TALs, we generated primary cultures of rat TALs as described [88]. NKCC2-BAD
specific metabolic biotinylation and labeling in rat TAL cells was performed as explained
in Aim 1 for imaging by TIRF microscopy. Then, we monitored the disappearance of
surface NKCC2 puncta from the apical membrane of rat TAL cells over 20 minutes at
37ºC. We observed that the number of surface NKCC2 puncta gradually decreased
over time (Figure 14) at a rate of 1.09 ± 0.08 % per minute, a surrogate of constitutive
NKCC2 endocytic rate.

Taken together, these data indicated that single-molecule

biotinylation of surface NKCC2-BAD and apical TIRF imaging can be used to monitor
NKCC2 endocytosis in TAL cells.
Figure 14: Graphical representation of
change in number of NKCC2 surface
puncta over time in rat TAL cells. N = 5, * p
< 0.01 vs. initial number of surface puncta.

Conclusion
We show here that site-specific labeled NKCC2 referred as NKCC2 puncta were
observed to disappear from the TIRF field indicating an endocytic event which led to
decrease in the number of surface puncta at a rate synonymous with the rate of NKCC2
endocytosis.

Treating cells with a cholesterol chelating agent (MβCD) completely

blocked NKCC2 endocytosis and disappearance of surface puncta. We conclude that
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TIRF microscopy of labeled NKCC2 is appropriate for dynamic and real time imaging of
individual endocytic events at the apical membrane of MDCK cells and TAL cells and
can be extended to study dynamic internalization events of other proteins.
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CHAPTER 3 - ROLE OF ALMS1 IN NKCC2 ENDOCYTOSIS AND THICK
ASCENDING LIMB FUNCTION AND BLOOD PRESSURE
Introduction
Increased NKCC2 activity and apical trafficking are associated with salt sensitive
hypertension in rodents and humans [25-31]. NKCC2 endocytosis has been shown to
be important in maintaining surface NKCC2 levels [37,38]. Despite its importance, the
regulation of NKCC2 endocytosis is poorly understood. MAL/VIP17 has been shown to
interact with a domain in the carboxyl-terminus of NKCC2 and regulate NKCC2
internalization [49]. To discover novel proteins that interact with this region of NKCC2
and play a role in NKCC2 endocytosis, we followed a targeted proteomics approach.
We identified a new protein not known to be previously expressed in the TAL - Alström
syndrome 1 (ALMS1). In this chapter we tested whether ALMS1 is involved in NKCC2
endocytosis to maintain surface NKCC2 levels, NKCC2-mediated NaCl reabsorption
and therefore in regulating blood pressure and inducing salt sensitivity. We divided this
chapter into two additional aims. In Aim 3 we tested whether ALMS1 interacts with the
C-terminus region of NKCC2 and mediates endocytosis thereby decreasing steadystate surface NKCC2 expression. In Aim 4 we tested whether inhibition of ALMS1
expression increases NKCC2-mediated NaCl reabsorption in the TAL and therefore
elevates blood pressure and induces salt sensitivity.
Aim 3: Hypothesis: ALMS1 binds the C-terminus region of NKCC2 and mediates
NKCC2 endocytosis thereby decreasing steady-state surface NKCC2 expression
in the TAL.
Rationale
NKCC2 surface levels are maintained by a balance between NKCC2
endocytosis, recycling and exocytosis. We showed that NKCC2 undergoes constitutive
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endocytosis and inhibition of endocytosis enhanced surface NKCC2 and NaCl
reabsorption by the TALs [33,37,38], indicating a direct relationship between apical
NKCC2 abundance and NKCC2 activity.

Despite the importance of the endocytic

pathway, the molecular mechanisms that regulate NKCC2 endocytosis are not clear.
Only one protein has been described to bind and regulate NKCC2 endocytosis
(MAL/VIP17) [49]. This protein interacts with a 71-amino acid domain in the carboxylterminus of NKCC2 (C2-NKCC2) which has been shown to be important for NKCC2
apical targeting [81]. Thus, we hypothesized that proteins that bind to this domain may
play an important role in NKCC2 endocytosis.

We performed a proteomic-based

identification of glutathione-S-transferase (GST)-C2-NKCC2 interacting proteins in the
TAL and identified Alström syndrome 1 (ALMS1) protein as one of the interacting
partners. ALMS1 is known to play a role in trafficking of transporters such as glucose
transporter 4 (GLUT4) [69] and C-terminus of ALMS1 (C-ALMS1) interacts with several
proteins such as Myosin Vb (MYO5B), α-actinin (ACTN), Rad50 interactor 1 (RINT1)
that play a role in the endocytic pathway [70-73]. We tested the hypothesis that ALMS1
interacts with NKCC2 and stimulates its endocytosis to maintain NKCC2 surface levels.
To specifically address the role of ALMS1, we inhibited its expression by gene silencing
via short hairpin RNA (shRNA) and genetic deletion in rats.
Results
ALMS1 is expressed in the TAL
First, to study the localization of ALMS1 in the kidney, we performed immunofluorescent labeling of ALMS1 in rat kidney transverse section (Figure 15A).

We

observed that ALMS1 is expressed in TALs indicated by co-immunolabeling for NKCC2.
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Figure 15: Expression of ALMS1 in rat TAL. A) Co-immunolabeling for NKCC2 and ALMS1 in rat
kidney section. TAL: Thick Ascending Limb; CD: Collecting duct, n = 3, scale bars = 20 µm. B) Immunolabeling of ALMS1 in rat primary cultured cells, n = 3, scale = 5 µm. C) Representative Western blot of
ALMS1 (corresponding to ~230 kDa protein band) in rat TAL, n = 3. D) RT-PCR with A, B and C primers
for amplification of 3’, 5’ and middle region of ALMS1 mRNA in rat TAL, N = negative control.

We cultured primary TAL cells and immuno-labeled for ALMS1 (Figure 15B).

We

confirmed the expression of ALMS1 in TAL by Western blot as an expected 230 kDa
protein band (Figure 15C). We detected ALMS1 mRNA in rat TAL by RT-PCR (Figure
15D). All these data together indicate and confirm the expression of ALMS1 in rat TAL.
Identification of ALMS1 as an interacting partner of NKCC2 in the TAL
In order to test whether ALMS1 expressed in the TAL interacts with C2-NKCC2,
a region important for NKCC2 apical targeting, we followed a targeted proteomics
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approach. We designed a GST-fusion protein with C2-NKCC2 (GST-C2-NKCC2) and
used it as bait in GST pull-down assays from TAL lysates.

We characterized the

interacting proteins by liquid chromatography followed by mass spectrometry. Of all the
proteins identified, we focused on the proteins most likely to play a role in endocytosis
and blood pressure regulation, by applying the following criteria: 1) It is associated with
QTL for high blood pressure according to Rat Genome Database (RGD), 2) Has been
associated with blood pressure, cardiovascular or renal phenotype in humans in the
(NHGRI) genome-wide association studies (GWAS) catalog and the PheGenl database.
3) The known interacting partners according to STRING and EntrezGENE databases
are proteins of known relevance in cardiovascular and renal physiology. Of all the
proteins identified, ALMS1 was chosen as a candidate for further study (Figure 16).
Figure 16: GST pull-down of
ALMS1 in TAL lysate with C2NKCC2.
Unique
peptides
corresponding to ALMS1 picked
up by liquid chromatography-mass
spectrometry in Glutathione-Stransferase (GST) pull down
assay
using
GST-carboxylterminus of NKCC2 fusion protein
(GST-C2-NKCC2) or GST alone
(control) as baits in rat TAL
lysates.

C-ALMS1 interacts with NKCC2 and forms a part of its endocytic network
The carboxyl-terminus of ALMS1 is known to interact with endocytic proteins
such as MYO5B, RINT1, ACTN1/4 [70-73]. Therefore, we studied if C-ALMS1 also
interacts with NKCC2. To test this, we used truncated portions of ALMS1 C-terminus
(C-ALMS1 A/B) fused to GST (GST-C-ALMS1 A/B) as a bait in GST pull-down assay in
TAL lysates. GST alone was used as a negative control. We identified a region in
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ALMS1 that is able to pull down full length NKCC2 by Western blot (Figure 17A).
Someof the proteins identified by mass spectrometric analysis of C-ALMS1 A/B and C2A

Figure
17:
Carboxyl-terminus
ALMS1
interacts with NKCC2 and other endocytic
proteins. A) Representative Western blot
showing pull down of full-length NKCC2 with
GST-carboxyl-terminus ALMS1 fusion protein B
(GST-C-ALMS1 B) as bait in rat TAL lysate, n =
3. B) Ingenuity pathway network analysis (IPA) of
proteins pulled down with carboxyl-terminus
ALMS1 in rat TAL lysate analyzed by liquid
chromatography-mass spectrometry. Solid black
lines represents direct interaction, dotted lines
represents indirect interaction from IPA and blue
lines represent direct/indirect interaction from
GST-C-ALMS1 pull down data

B

NKCC2 pulled down proteins were phosphatidylinositol binding clathrin assembly
protein (PICALM1) and rabaptin (RABEP1; data not shown) respectively, that are
known to be involved in early endocytic pathway of other proteins. Ingenuity pathway
analysis (Figure 17B) of C-ALMS1 interactome indicated protein-protein interactions
among themselves and this suggested that these proteins may form a network of early
endocytic machinery of NKCC2 (See Table 2 for details on other pulled down proteins).
ALMS1 co-localizes with NKCC2 in the TAL
In isolated TAL preparations, we observed that ALMS1 was distributed along the
apical and sub-apical regions (Figure 18A), similar to the expression pattern of NKCC2
[35].
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Figure 18: Expression and
co-localization of ALMS1
with NKCC2 in apical and
sub-apical regions in rat
TAL. A) Immunostaining for
ALMS1 in isolated perfused rat
TAL. B) Co-immunolabeling of
ALMS1
and
internalized
surface NKCC2 in rat TAL
primary culture, n = 3. Merged
image from sub-apical plane (2
µm from the apical plane)
showing
co-localization
of
NKCC2 and ALMS1 in yellow
indicated by arrow. Colocalization analysis performed
with a Mander’s overlap
coefficient of > 0.95.

A

B

Immuno-labeling of ALMS1 in isolated, perfused rat TAL was performed and
imaged across transverse section and apical surface of TAL tubule by confocal
microscopy. In rat kidney sections, ALMS1 was seen to co-localize with NKCC2 (Figure
15A).

To test whether ALMS1 co-localizes with internalized NKCC2 in cultured rat

TALs, we fluorescently labeled surface NKCC2 at 4ºC with an antibody that recognizes
an epitope in an extracellular loop [88]. Following a 30 min period of endocytosis at
37ºC, we fixed the cells and labeled ALMS1. We observed that a fraction of ALMS1 colocalized with NKCC2 (Figure 18B).

Altogether these data indicate that ALMS1

interacts with C2-NKCC2 at the apical membrane and sub-apical space of TALs where
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a fraction of ALMS1 co-localizes with internalized NKCC2.
Generation of ALMS1
characterization

genetic

deletion

rat

model

and

its

phenotypic

To test our hypothesis in a stable genetic deletion animal model, we generated
ALMS1 knockout (ALMS1 KO) rats using zinc finger nuclease gene editing technology
in collaboration with the Gene Editing Rat Resource Center (GERRC) at the Medical
College of Wisconsin. Deletion of 17 base pairs in exon 1 of the ALMS1 gene results in
a premature stop codon to generate ALMS1 deletion rat model (Figure 19A). Specific
primer amplification followed by restriction digestion show heterozygous and
homozygous deletions (Figure 19B). Figure 19C shows a 90% reduction in ALMS1
expression in TALs from ALMS1 KO rats.
Since ALMS1 is known to be localized to the base of the cilia, a study showed
that knockdown of ALMS1 in mouse inner medullary collecting duct (mIMCD3) cell line
resulted in stunted and malformation of cilia [89]. However ALMS1 mutant mice models
show normal cilia length [67]. Thus, there is a controversy whether or not deletion of
ALMS1 caused malformation/stunted appearance of cilia in the kidney. We immunolabeled cilia in kidney sections from ALMS1 KO rats and WT rats and we found normal
ciliary staining in both groups, indicating normal ciliary development upon ALMS1
deletion in rats (Figure 20).
Previous reports have shown that transgenic ALMS1 knockout mice are
characterized with age dependent metabolic syndrome and kidney damage.

We

measured body weight of wild-type (WT) and ALMS1 KO rats and observed that the
body weight of ALMS1 KO rats is slightly higher than WT only after 10-11 weeks of age.
Blood glucose and plasma insulin were not different between the groups by 6-12 weeks
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of age. Gross kidney anatomy looked normal in histological sections from 6-12 week
old rats (Figure 21). At 6-12 weeks of age, ALMS1 KO rats had a similar kidney weight
and GFR as that of the WT rats (Table 1).
A

B

C

Figure 19: Generation and genotyping of ALMS1
KO rats. A) Zinc finger nucleases target 17 base pairs
in exon 1 of the ALMS1 gene leading to a frame shift
and causing a pre-mature stop codon in exon 2. B)
PCR using exon 1 specific primers followed by Nci1
restriction digestion generated 365 bp and
indistinguishable 181/ 201 bp fragments in ALMS1 KO
and WT rat ear snips, respectively. C) Representative
Western blot for ALMS1 in TAL lysates from WT and
ALMS1 KO rats, n = 3, * p < 0.05 vs. WT.

These data indicate that at this age, ALMS1 KO rats do not significantly develop
metabolic syndrome or kidney damage. To prevent the effect of potentially confounding
phenotypes that are expected in older rats, we used rats of age 6-12 weeks for our
study.
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Figure 20: Immuno-fluorescent staining
for cilia in kidney slices from WT and
ALMS1 KO rats. A) Scale bar = 15 µm, n =
5. B) Quantification of cilia length in WT and
ALMS1 KO kidney slices (represented in
white square), n = 40-50 per slide.

Figure 21: Light micrographs of
kidney slices from WT and
ALMS1 KO rats. H&E staining,
n = 3.

ALMS1 KO rats have enhanced NKCC2 levels at the apical surface in TAL
To test whether genetic deletion of ALMS1 in rats leads to enhanced surface
NKCC2 in TALs, we performed surface biotinylation in TAL suspension obtained from
WT and ALMS1 KO rats. Western blot for NKCC2 revealed that ALMS1 KO rats have
higher NKCC2 at the surface in TAL compared to WT (ALMS1 KO: 13.8 ± 1.2% vs. WT:
8.1 ± 1.1%, n = 6, p < 0.05; Figure 22A). Total NKCC2 expression was not different
between the groups (Figure 22B). GAPDH served as a surface biotinylation control.
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Table 1: Physiological parameters measured in young (6- 12 week old) WT and
ALMS1 KO rats.
Physiological parameters

WT (6-12 weeks)

ALMS1 KO (6-12 weeks)

Body weight (g)

309 ± 10

331 ± 11*

Blood glucose (mg/dl)

134 ± 10

138 ± 12

Plasma insulin (ng/ml)

0.45 ± 0.15

0.7 ± 0.1

Kidney weight (g)

2.75 ± 0.1

2.53 ± 0.13

GFR (ml/min/gkw)

0.94 ± 0.16

1.07 ± 0.36

For plasma insulin & blood glucose - n = 3; body weight - n = 5; kidney weight & GFR - WT: n
= 6, ALMS1 KO: n = 5, * p < 0.05 vs. WT.

Phosphorylation of NKCC2 is unaffected by ALMS1 deletion in rats
To test whether deletion of ALMS1 leads to changes in NKCC2 phosphorylation,
we measured NKCC2 phosphorylation levels with antibodies directed specifically to
Threonine (Thr96/101) and Serine (Ser126) residues of NKCC2 and found no significant
differences between TALs from WT and ALMS1 KO rats (Figure 23A and Figure 23B).
Developing ALMS1 shRNA for renal medulla-specific knockdown of ALMS1
We then tested whether the effect of ALMS1 deletion on surface NKCC2 was
due to decreased ALMS1 expression in the renal tubule.

For this, we bought a

commercially available ALMS1 shRNA. To test its mRNA knockdown efficacy in a rat
cell line, we first studied if ALMS1 mRNA is expressed in normal rat kidney (NRK-52E)
cell line. Upon transfection with ALMS1 shRNA in this cell line, we observed 78%
decreased expression of ALMS1 mRNA measured by RT-PCR (Figure 24A). We then
silenced ALMS1 in the renal medulla by adenovirus-mediated gene silencing (Figure
24B).
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Figure 22: Deletion of ALMS1
in rats increases steady-state
surface NKCC2 in TALs. A)
Surface NKCC2 measured by
surface
biotinylation
assay
followed by Western blot for
NKCC2 and quantified as
percentage of total NKCC2 n =
6, * p < 0.05 vs. WT. B) Total
NKCC2 expression is similar in
TALs of WT and ALMS1 KO
rats, n = 6. C) Schematic
protocol of surface biotinylation
to measure surface NKCC2 in
TAL suspension.

For this, we injected adenoviral ALMS1 shRNA into the outer medulla of the left
kidney of normal rats while the right kidney injected with buffer served as the sham
control.

After 7 days of adenoviral ALMS1 shRNA injection, we observed 80%

decrease in ALMS1 mRNA (normalized value ALMS1 shRNA: 0.19 ± 0.04 vs. control: 1,
n = 3, * p < 0.01) (Figure 24C) and a 60% decrease in ALMS1 protein expression
(normalized value ALMS1 shRNA: 0.39 ± 0.2 vs. control: 1, n = 4, * p < 0.05) (Figure
24D) in isolated TALs, together indicating an effective ALMS1 knockdown.
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Figure 23: Phosphorylated
NKCC2 level is similar in TALs
from WT and ALMS1 KO rats.
A) Phosphorylated Thr (96/101)
NKCC2 and B) Phosphorylated
Ser (126) NKCC2 in TALs from
WT and ALMS1 KO rats, n = 3.

An acute silencing of ALMS1 by ALMS1 shRNA in the TAL leads to higher surface
NKCC2
Surface NKCC2 expression was enhanced in TALs from ALMS1 shRNA injected
kidney compared to control injected kidney (ALMS1 shRNA: 11.1 ± 1.6% vs. control: 6.6
± 0.8%, n = 5, * p < 0.05) and there was no change in total NKCC2 expression
(normalized value ALMS1 shRNA: 0.93 ± 0.07 vs. control: 1, n = 5, ns) (Figure 25 A, B).
GAPDH served as surface biotinylation control. These data indicate that enhanced
NKCC2 in the TALs of ALMS1 KO rats is due to the effect of deletion of ALMS1 in TALs
and not an effect of ALMS1 deletion in other organs.
Higher surface NKCC2 in TALs of ALMS1 KO rats is due to decreased NKCC2
endocytosis
To test our hypothesis that increased surface NKCC2 in ALMS1 KO rats is due to
decreased NKCC2 endocytosis in the TAL, we performed a modified surface
biotinylation protocol to measure NKCC2 internalized fraction at 37ºC (Figure 26C).
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Figure 24: Inhibition of ALMS1 mRNA and protein expression upon ALMS1 shRNA transfection. A)
ALMS1 shRNA transfected in NRK-52E cells and mRNA quantified by RT-PCR, n = 3, * p < 0.01 vs.
control. B) ALMS1 adenoviral shRNA transduced in vivo into renal outer medulla of Sprague Dawley rats
and ALMS1 mRNA expression quantified by RT-PCR, n = 3, * p < 0.01 vs. control. C) ALMS1 adenoviral
shRNA transduction into renal outer medulla of SD rats and ALMS1 protein quantified by Western blot, n
= 4, * p < 0.05 vs. control.

We observed that the internalized fraction of NKCC2 after warming to 37ºC was
significantly lower in TALs from ALMS1 KO rats (Figure 26A).

We found that

internalized NKCC2 measured as percent of baseline total surface NKCC2 was
significantly lower in ALMS1 KO rats compared to WT (ALMS1 KO: 13.1 ± 1.4% vs. WT:
28.2 ± 2.8% over 20 minutes, n = 5, * p < 0.05; Figure 26B), suggesting decreased
NKCC2 endocytic rate in TALs from ALMS1 KO rats (ALMS1 KO: 0.65 ± 0.07 %/min vs.
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WT: 1.41 ± 0.14 %/min).
A

B

Figure 25: Knockdown of ALMS1 by ALMS1 shRNA transduction in renal outer medulla leads to
increased steady-state surface NKCC2 in TALs. A) Surface NKCC2 was quantified by surface
biotinylation assay and expressed as percentage of total NKCC2. N = 5, * p < 0.05 vs. control. B) Total
NKCC2 expression does not change upon ALMS1 mRNA knockdown in renal outer medulla of SD rats, n
= 5.

Conclusion
We showed that C-ALMS1 interacts with C2-NKCC2 in rat TALs. We also
showed that ALMS1 and NKCC2 co-localize in rat TAL primary culture and in rat
kidney sections. Ingenuity pathway analysis of ALMS1 interacting proteins suggested
that they may together form NKCC2 endocytic machinery. In TALs from ALMS1 KO,
surface NKCC2 measured as a percentage of total NKCC2 at the surface was higher
compared to WT. Total NKCC2 expression was not different between strains. We
also showed that the effect of enhanced NKCC2 surface abundance is due to ALMS1
inhibition in the renal tubule and not due to deletion of ALMS1 in other organs. The
increase in surface NKCC2 is due to lower endocytosis because the rate of NKCC2
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internalization was lower in TALs from ALMS1 KO rats. We conclude that ALMS1
interacts with carboxyl-terminus of NKCC2, stimulates NKCC2 endocytosis thereby
decreasing steady-state surface NKCC2. The significance and in depth interpretation
of all these observations will be addressed in the discussion in Chapter 5.
A

B

C
Figure 26: NKCC2 endocytosis is
decreased in TALs from ALMS1
KO rats. A) NKCC2 internalized
fraction and B) NKCC2 endocytosis
measured by modified surface
biotinylation assay and expressed
as percent of total surface NKCC2,
n = 5, * p < 0.05 vs. WT. C)
Schematic protocol of modified
surface biotinylation assay to
measure NKCC2 internalization in
TAL suspensions.

Aim 4: Hypothesis: ALMS1 decreases NKCC2-mediated NaCl reabsorption by the
TAL, thereby plays a role in salt sensitive hypertension
Rationale
Enhanced NKCC2 activity is associated with salt sensitive hypertension but the
underlying molecular mechanisms are not very well elucidated [25-31]. Our current
understanding of the complex genetic architecture of hypertension and salt sensitivity
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relies heavily on identification of several susceptibility loci through population-based
association studies. In this regard, genetic loci such as uromodulin (UMOD) [90-94] and
ALMS1 [56] among others were identified for genetic risk associated with hypertension.
The role of UMOD in regulating NKCC2 activity and salt sensitive hypertension has
been well characterized [95]. However, very little is known about the role of ALMS1 or
its link with NKCC2.

In a targeted proteomics screen, we identified ALMS1 as an

interacting partner of NKCC2.

We tested the hypothesis that inhibition of ALMS1

increases NKCC2-mediated NaCl reabsorption, thereby elevates blood pressure and
induces salt sensitivity. To specifically address the role of ALMS1, we inhibited ALMS1
expression by genetic deletion of ALMS1 in rats.
Results
ALMS1 KO rats are hypertensive and salt sensitive
To test our hypothesis that genetic deletion of ALMS1 in rats leads to increased
blood pressure, we used 7-9 week old ALMS1 KO rats and WT littermates fed on a
normal salt diet (0.22% Na) to measure systolic blood pressure by tail cuff
plethysmography.

We observed that ALMS1 KO rats have a higher systolic blood

pressure and were hypertensive (ALMS1 KO: 147 ± 3 mmHg vs. WT: 135 ± 3.5 mmHg,
n = 5, * p < 0.05; Figure 27A). Mean arterial pressure (MAP) measured by intra-arterial
catheter in anesthetized rats was also found to be higher in ALMS1 KO rats (ALMS1
KO: 141 ± 5 mmHg vs. WT: 99 ± 6 mmHg, n = 5, * p < 0.005; Figure 27B).
To test our hypothesis that genetic deletion of ALMS1 in rats induces salt
sensitivity, we used 8-10 week old ALMS1 KO rats and WT littermates to measure
systolic blood pressure by tail cuff plethysmography in response to increasing salt

39
(0.4%) in their drinking water after measuring baseline blood pressures as mentioned
above. We found that upon the salt challenge, the systolic blood pressure increased
significantly higher in ALMS1 KO rats compared to their WT littermates (∆SBP ALMS1
KO: 17 ± 4 mmHg vs. ∆SBP WT: 5.1 ± 4.1 mmHg, n = 5, $ p < 0.05; Figure 27A).
A

B

Figure 27: ALMS1 KO rats are hypertensive and salt sensitive. A) Baseline systolic blood pressure
measured on 0.22% salt diet. The rats were then challenged with additional 0.4% NaCl in their drinking
water to measure salt sensitivity, n = 5, * p < 0.05 vs. WT and # p < 0.01 vs. baseline. B) Mean arterial
pressure was measured by intra-arterial catheter, n = 5, * p < 0.005 vs. WT.

ALMS1 KO rats have lower plasma renin activity
To test whether renin-angiotensin system contributes to the hypertension
observed in ALMS1 KO rats, we measured plasma renin activity (PRA) in ALMS1 KO
rats and we found that PRA was significantly lower in ALMS1 KO rats compared to WT
rats (ALMS1 KO: 1.28 ± 0.32 ng Ang I/ml/hr, n = 5 vs.
WT: 2. ± 0.28 ng Ang I/ml/hr, n = 6, * p < 0.05; Figure
28) indicating that hypertension and salt sensitivity in
ALMS1 KO rats is independent of the reninangiotensin system.
Figure 28: ALMS1 KO rats have low plasma renin activity.
ALMS1 KO: n = 5, WT: n = 6, * p < 0.05 vs. WT.
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ALMS1 KO rats have higher NKCC2 activity measured in vivo
To test our hypothesis that deletion of ALMS1 increases blood pressure due to
enhanced NaCl reabsorption in the TAL, we measured NKCC2-mediated NaCl transport
in vivo. We housed the animals in metabolic cages and collected 24 hour urine. At
baseline, we found that the urine volume collected was not significantly different
between the groups (ALMS1 KO: 9.2 ± 0.7 ml/24 hr, n = 5 vs. WT: 10 ± 0.8 ml/24 hr, n =
4, ns; Figure 29A). However, the urine osmolality (ALMS1 KO: 2560 ± 63.4 mOsm/kg
water, n = 5 vs. WT: 1724 ± 73.1 mOsm/kg water, n = 3, * p < 0.005; Figure 29B) was
significantly higher in ALMS1 KO rats indicating higher urine concentrating capacity
which is associated with a higher NKCC2-mediated NaCl reabsorption via the
generation of high medullary interstitial osmolarity [23]. To measure NKCC2-mediated
NaCl reabsorption in vivo, we measured acute diuretic and natriuretic effect of NKCC2
inhibitor bumetanide.
Figure 29: ALMS1 KO rats have
better
urine
concentrating
capacity. A) Urine volume and B)
Urine osmolality measured in ALMS1
KO rats, * p < 0.005 vs. WT.

We found that urine flow rate (ALMS1 KO: 3.1 ± 0.32 ml/8 hours, n = 5 vs. WT:
1.6 ± 0.13 ml/8 hours, n = 4, * p < 0.025) and urinary sodium excretion rate (ALMS1 KO:
485.2 ± 37.1 µmoles/8 hours, n = 5 vs. WT: 221.8 ± 32 µmoles/8 hours, n = 4, * p <
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0.025) until 8 hours after bumetanide treatment was significantly higher in ALMS1 KO
rats compared to WT rats, indicative of a higher NKCC2 activity in ALMS1 KO rats
(Figure 30A, 30B).
A

B

Figure 30: ALMS1 KO rats have higher bumetanide-induced diuresis and natriuresis. A) Urine flow
rate and B) Urinary sodium excretion rate measured until 8 hours after (sub-maximal dose) of 5 mg/ml
bumetanide, ALMS1 KO: n = 5, WT: n = 4, * p < 0.025 vs. WT, # p < 0.025 vs. baseline.

We then tested whether higher NKCC2-mediated NaCl reabsorption in the TAL is
associated with a decreased ability to excrete a saline/water load.

For this, we

anesthetized and instrumented rats and performed 3% volume expansion (VE) with
respect to their body weight. We collected urine at every 30 min intervals and found
that the cumulative urine volume (ALMS1 KO: 0.7 ± 0.24 ml, n = 8 vs. WT: 1.77 ± 0.4
ml, n = 6, * p < 0.05) and urinary sodium excretion (ALMS1 KO: 72.5 ± 37.9 µmoles, n =
8 vs. WT: 278.4 ± 64.5 µmoles, n = 6, * p < 0.05) after 3% VE (60 to 210 min; corrected
to their respective baselines) indicated by shaded regions was significantly lower in
ALMS1 KO rats (Figure 31 A, B).
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Figure 31: ALMS1 KO rats have reduced capacity to eliminate volume/salt load. Cumulative A) urine
volume B) urinary sodium excreted upon 3% volume expansion, ALMS1 KO: n = 8, WT: n = 6 * p < 0.05.

Conclusion
We show that deletion of ALMS1 causes higher urine concentrating capacity in
rats and higher bumetanide induced diuresis and natriuresis. The excretory capacity
upon challenge with salt and water load decreased in ALMS1 KO rats. We observed
that deletion of ALMS1 in rats increased systolic and mean blood pressure and
hypertension develops independent of renin-angiotensin system. Taken together, these
data indicate that ALMS1 KO rats have a higher NKCC2-mediated Na+ absorption and
thus a decreased ability to excrete a salt and volume load. These may be in part
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responsible for hypertension observed in these rats. The significance and in depth
interpretation of these observations will be addressed in Chapter 5.
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CHAPTER 4 - ALMS1 IS IMPORTANT FOR MAINTAINING METABOLIC FUNCTION
IN RATS
Introduction
In humans, mutations in the ALMS1 gene causes Alström syndrome which is
characterized by obesity, type-2 diabetes in addition to hypertension [50-53]. ALMS1
transgenic mice model recapitulated age-dependent metabolic syndrome as observed
in humans and also exhibited sex-based differences in the development of metabolic
syndrome [67,69]. In this chapter we characterized sex-based differences in ALMS1
KO rats for their metabolic function.
Aim 5: Hypothesis: Deletion of ALMS1 causes age-dependent metabolic
syndrome in rats
Rationale
Mice with ALMS1 mutations are characterized with sex differences in the
development of age dependent metabolic syndrome. In this aim we tested whether
ALMS1 KO rats recapitulated metabolic syndrome as observed in humans and mice
with mutation in the ALMS1 gene.
Results
6-12 week old ALMS1 KO rats do not develop metabolic syndrome
Table 1 clearly shows that 6-12 week old ALMS1 KO rats have normal plasma
leptin, plasma insulin, random blood glucose but only a slightly elevated body weight.
This indicates that young ALMS1 KO rats do not develop metabolic syndrome as
indicated previously in ALMS1 transgenic mice models. Therefore we tested whether
16-18 week old ALMS1 KO rats develop metabolic syndrome.
Old ALMS1 KO rats develop obesity as they age
We then tested whether older ALMS1 KO rats are obese. We measured their
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Figure 32: Sex-based
characterization
of
obesity in ALMS1 KO
rats. A) Body weight
differences between the
sexes, n = 5, * p < 0.005
vs. WT. B) Representative
image of old female
ALMS1 KO and WT rats.
C&D) Abdominal fat pad
weight in both sexes, n =
3, * p < 0.005 vs. WT.
E&F) Daily average food
intake in both sexes, n = 5,
* p < 0.01 vs. WT. G&H)
Plasma
leptin
concentration
in
both
sexes, n = 4, * p < 0.01 vs.
WT.
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body weights and found that both male and female ALMS1 KO rats have a significantly
higher body weight compared to their wild type littermates starting at age week 9 in
males and week 7 in females (Figure 32A).

In 16-18 week old ALMS1 rats, we

measured abdominal fat mass and found that it was higher in both male (ALMS1 KO:
30.9 ± 3.4 g vs. WT: 10.1 ± 2.5 g, n = 3, * p < 0.005) and female ALMS1 KO rats
(ALMS1 KO: 36.9 ± 3.7 g vs. WT: 7.9 ± 1.8 g, n = 3, * p < 0.005) compared to their wild
type littermates (Figure 32 C&D) and appeared obese at 16 weeks of age
(representative image of female rats; Figure 32B). We then measured food intake in
16-18 week old ALMS1 KO rats and found that both male (ALMS1 KO: 26.9 ± 3.1 g/day
vs. WT: 19 ± 2.5 g/day, n = 5, * p < 0.01) and female ALMS1 KO rats (ALMS1 KO: 25.1
± 2.5 g/day vs. WT: 12.9 ± 0.95 g/day, n = 5, * p < 0.01) are hyperphagic (Figure 32
E&F), a potential cause for their obesity. We then measured plasma leptin levels in 1618 week old ALMS1 KO and found that both male (ALMS1 KO: 68.3 ± 10.5 ng/ml vs.
WT: 2.75 ± 1.1 ng/ml, n = 4, * p < 0.01) and female ALMS1 KO rats (ALMS1 KO: 64.1 ±
15.9 ng/ml vs. WT: 0.9 ± 0.3 ng/ml, n = 4, * p <0.01) were hyperleptinemic (Figure 32
G&H).

These data indicate that older ALMS1 KO rats may have a deficient leptin

signaling leading to its decreased ability to suppress their food intake, indicative of leptin
resistance.
Old ALMS1 KO rats exhibit hypertriglyceridemia
We measured plasma lipid profile and we found that only triglyceride levels were
significantly elevated in both male (ALMS1 KO: 633.4 ± 221.2 mg/dl, n = 7 vs. WT:
109.4 ± 16.2 mg/dl, n = 4, * p < 0.01) and female ALMS1 KO rats (ALMS1 KO: 595.9 ±
200.1 mg/dl, n = 7 vs. WT: 55.6 ± 12.5 mg/dl, n = 4, * p < 0.05). Significant differences
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were observed in serum cholesterol (ALMS1 KO: 151.9 ± 37.8 mg/dl, n = 7 vs. WT: 81.9
± 4.9 mg/dl, n = 4, * p < 0.05) high density lipoprotein (ALMS1 KO: 41.9 ± 7.9 mg/dl, n =
7 vs. WT: 67.8 ± 2.2 mg/dl, n = 4, * p < 0.05) low density lipoprotein levels (ALMS1 KO:
32.2 ± 6.4 mg/dl, n = 7 vs. WT: 15 ± 1.4 mg/dl, n = 4, * p < 0.05) only in female ALMS1
KO rats but were not different in male ALMS1 KO rats (Figure 33 A&B).
A

B

Figure 33: Sex-based differences in serum lipid profiling in ALMS1 KO rats. A) Males ALMS1 KO: n
= 7, WT: n = 4, * p < 0.01 vs. WT and B) Females ALMS1 KO: n = 7, WT: n = 4, * p < 0.05 vs. WT.

Old ALMS1 KO rats are hyperinsulinemic
We tested whether ALMS1 KO rat model reproduced metabolic dysfunction as
seen in the ALMS1 mutant mice model. We measured random blood glucose by tail
snips and we found that it was not different between the groups in either males (ALMS1
KO: 134.5 ± 9.4 mg/dl vs. WT: 132.3 ± 9.9 mg/dl, n = 3) or females (ALMS1 KO: 126 ±
3.8 mg/dl vs. WT: 130.3 ± 3.4 mg/dl, n =3) (Figure 34 A&B). However, the fasting blood
glucose was measured to be significantly higher in both male (ALMS1 KO: 108 ± 4
mg/dl vs. WT: 61 ± 17 mg/dl, n = 3, * p < 0.05) and female (ALMS1 KO: 100 ± 13 mg/dl
vs. WT: 71 ± 6 mg/dl, n = 3, * p < 0.05) rat groups (Figure 34 C&D). Plasma insulin was
measured to be significantly higher in both males (ALMS1 KO: 8.1 ± 4.3 ng/ml, n = 5 vs.
WT: 1.38 ± 0.73 ng/ml, n = 3, * p < 0.05) and females (ALMS1 KO: 8.5 ± 1.9 ng/ml, n =
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9 vs. WT: 0.93 ± 0.2 ng/ml, n = 6, * p < 0.05) (Figure 34 E&F) indicating ALMS1 KO rats
are hyperinsulinemic.
A
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Figure 34: Sex-based characterization of metabolic parameters in ALMS1 KO rats. A&B) Random
blood glucose in both the sexes, n = 3, C&D) Fasted-blood glucose in both sexes, n = 3, * p < 0.05 and
E&F) Plasma insulin in both sexes, male ALMS1 KO: n = 5 & WT: n = 3, female ALMS1 KO: n = 9 & WT:
n = 6, * p < 0.05 vs. WT.
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Together, these data indicate that both male and female ALMS1 KO rats may
have a deficient insulin signaling leading to its decreased ability to lower fasting blood
glucose, indicative of insulin resistance.
Old ALMS1 KO rats are hypertensive
To test whether obese ALMS1 KO rats are hypertensive, we measured their
systolic blood pressure by tail cuff plethysmography and found that both male (ALMS1
KO: 151 ± 5.1 mmHg vs. WT: 125 ± 4.2 mmHg, n = 6, * p < 0.05) and female (ALMS1
KO: 199 ± 7.1 mmHg vs. WT: 134 ± 3.3 mmHg, n = 6, * p < 0.0001) ALMS1 KO rats are
hypertensive (Figure 35A).

Systolic blood pressure in female ALMS1 KO rats was

higher than that of their male counterparts (Female ALMS1 KO: 199 ± 7.1 mmHg vs.
male ALMS1 KO: 151 ± 5.1 mmHg, n = 6, $ p < 0.0001) (Figure 35B).
A

B

Figure 35: Systolic blood pressure measurement in both sexes of ALMS1 KO rats.
A) N = 6, * p < 0.05 vs. WT. B) N = 6, * p < 0.0001 vs. WT

Conclusion
We showed that old male ALMS1 KO rats are hyperinsulinemic, obese,
hyperphagic, hypertriglyceridemic and hyperleptinemic. Insulin and leptin resistance
may develop secondarily to obesity since younger non-obese ALMS1 KO rats are
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neither hyperinsulinemic nor hyperleptinemic. We also show that obese ALMS1 KO
rats have a higher systolic blood pressure. Female ALMS1 KO exhibit all the above
phenotypes in addition to having high serum cholesterol, LDL, low HDH levels and
higher systolic blood pressure. The significance and in depth interpretation of all these
observations will be addressed in the discussion in Chapter 5.
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CHAPTER 5 - CONCLUDING REMARKS
Summary of results
In this study we have shown that:
1.

TIRF microscopy allows imaging of NKCC2 specific labeled molecules in TAL
cells.

2.

TIRF microscopy allows real-time monitoring of NKCC2 endocytosis in TAL cells.

3.

ALMS1 is expressed apically and sub-apically in the TAL.

4.

Carboxyl-terminus NKCC2 domain known to determine its apical targeting
interacts with ALMS1.

5.

Carboxyl-terminus ALMS1 interacts with NKCC2.

6.

ALMS1 and NKCC2 co-localize in kidney sections and in rat TAL.

7.

ALMS1 expression is required to maintain normal systolic and mean arterial
pressure in rats.

8.

ALMS1 expression is required for normal NKCC2-mediated NaCl reabsorption in
the rat TAL.

9.

ALMS1 expression is required for effective elimination of water/salt load by rats.

10.

ALMS1 maintains normal NKCC2 surface expression in rat TAL.

11.

ALMS1 stimulates NKCC2 endocytosis in the rat TAL.

12.

ALMS1 is required to maintain normal metabolic function in rats.

13.

Deletion of ALMS1 in female rats causes more severe phenotype in terms of lipid
profiles, obesity and hypertension.

Discussion
Importance of studying NKCC2 endocytosis
NKCC2 mediates NaCl reabsorption in the thick ascending limb of the loop of
Henle [30,31]. NKCC2 activity is shown to be enhanced in salt sensitive hypertension
[25-31]. NKCC2 activity is regulated by 1) phosphorylation at threonine (96/101) by
STE20- and SPS1-related proline and alanine-rich kinases (SPAK) and oxidative stress-
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responsive kinase 1 (OSR1) [49,96-98] and at Ser(126) site by PKA [99], 2) proteinprotein interactions [49,100-102] and 3) protein trafficking [37,38]. While the regulation
of NKCC2 via phosphorylation has been well studied, very little is known about
mechanisms and protein-protein interactions which regulate NKCC2 apical trafficking.
NKCC2 surface abundance is maintained by a balance between NKCC2 exocytosis,
recycling and NKCC2 internalization [36-38].

Our lab has previously shown that

constitutive NKCC2 endocytosis is important to maintain baseline NaCl absorption by
the TAL because inhibition of endocytosis increased surface NKCC2 abundance and
increased chloride absorption by TAL [37,38].

This highlights the importance of

understanding the machinery that regulates NKCC2 internalization from the apical
membrane in TALs.

However, currently available techniques to study NKCC2

endocytosis are unsuccessful in providing time resolution of the dynamic process
achieved by live cell imaging. TIRF microscopy is employed for real time visualization
of dynamics of molecules at or near the cell surface in real time. This method has
yielded detailed dynamic information about clathrin-coated vesicle trafficking at the
plasma membrane [41-46].
Traditional surface biotinylation technique which is currently used to study
NKCC2 endocytosis has numerous limitations. It uses NHS-SS-biotin that reacts and
biotinylates accessible lysine residues in all surface proteins.

Thus, it does not

differentiate NKCC2 from other surface proteins in the TIRF field.

Therefore, we

engineered NKCC2-BAD construct which provides the advantage of selective NKCC2
biotinylation by BirA to study real time NKCC2 endocytic events at the plasma
membrane of polarized MDCK cells and TALs by TIRF microscopy.
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Monitoring real-time NKCC2 endocytosis by TIRF microscopy
To perform live cell imaging for obtaining the rate of NKCC2 endocytosis, the
apical surface of MDCK cells and rat TAL primary cells were imaged every second over
20 minutes at 37ºC.

On the TIRF field, NKCC2 distribution was observed to be

heterogeneous and individual fluorescent entities were observed, referred to as puncta.
These puncta on the TIRF field appeared to be clustered and exhibited exponential
decrease in intensity within about 1-2 seconds which lead to a progressive decrease in
the number of total surface puncta at a rate analogous to constitutive NKCC2
endocytosis as previously measured in TALs [37,38].

The exponential decrease in

intensity was confirmed to be due to the internalization of NKCC2 by pre-treating the
cells with MβCD that is known to block endocytosis [37,38]. MβCD was previously
shown to block NKCC2 endocytosis by depleting membrane cholesterol and not by
other mechanisms [37,38]. In contrast, our lab showed that MβCD blocks clathrin-, and
lipid raft-mediated endocytosis in thick ascending limbs [38]. Upon pre-treatment with
MβCD, we observed that the number of initial puncta remained unchanged over time.
This suggested that TIRF microscopy of labeled NKCC2 allows imaging of single
endocytic events with a time resolution of 1-2 seconds.
Choice of fluorescent dyes for monitoring real time NKCC2 endocytosis by TIRF
microscopy
Imaging during 20 minutes prevents photobleaching of Alexa Fluor dyes during
the prolonged duration of image acquisition. It has been reported that a resolution time
shorter than 1-2 seconds is possible with usage of fluorescent Quantum Dots because
they are brighter and more photo-stable. However, Quantum Dots exhibit fluorescent
intermittency or blinking. This is a discontinuous and random emission of light from
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fluorescent sources due to random switching between bright fluorescent and nonemissive periods [103].

We observed this phenomenon when using streptavidin-

Quantum Dots and due to this phenomenon of blinking, disappearance of fluorescence
can be mistaken for an endocytic event. Thus, we used Alexa Fluor dyes covalently
linked to streptavidin instead to overcome blinking. However very recently, non-blinking
Quantum Dots have been developed to overcome this disadvantage and provide higher
quantum yield compared to Alexa Fluor [104,105].
NKCC2 oligomerization
On the TIRF field, we observed that NKCC2 puncta are heterogeneously
distributed in the apical surface highly confined to clusters or discrete domains which
may suggest homo-oligomerization of NKCC2 [106]. A similar distribution pattern was
observed by confocal imaging of TAL cells after labeling apical surface NKCC2 [88].
However, the usage of tetravalent streptavidin-conjugated dyes possibly lead to
multimerization of the mono-biotinylated NKCC2-BAD molecules and may be a potential
cause of such a heterogenous pattern [41]. Nonetheless, the rate of endocytosis in rat
TAL cells by TIRF microscopy was calculated to be 1.09 ± 0.08 % per minute,
consistent with that calculated by surface biotinylation methods in native TAL using
NHS-SS-biotin [37]. Therefore, it is possible that clustering of NKCC2 may be due to
targeting of the co-transporter to specialized membrane domains for efficient and
concerted activity as reported for other co-transporters [107-110] and not an artifact due
to the method used. Exogenous over-expression seems to be a valid concern since it
may cause aggregation of the expressed protein. For this, we measured its impact on
rate of NKCC2 endocytosis by changing the concentration of the virus used for
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transduction and found no significant effect (data not shown). This suggested that overexpression does not affect NKCC2 endocytosis.

While the reason for clustering of

surface NKCC2 is unclear, our data clearly point that labeling with tetravalentstreptavidin did not affect the rate of NKCC2 endocytosis in MDCK or TAL cells. Thus,
we conclude that site-specific biotinylation allows for specific labeling of NKCC2 at the
cell surface to visualize its real-time endocytosis in live cells by TIRF microscopy of
apical membranes in polarized MDCK and TAL cells.
Potential application of TIRF microscopy in studying dynamics of NKCC2
endocytosis
Real time imaging by confocal or TIRF microscopy has been very useful in
studying how protein-protein interactions [48,111-113], protein motifs/domains [114] and
signaling pathways [115,116] regulate trafficking of membrane transporters. Application
of novel single molecule tagging technologies coupled with real time tracking has
provided information on apical targeting of receptors to highly specialized membrane
domains, which can lead to clustering for efficient signal transduction [105,108-110]
following stimulation by ligands [117]. Therefore, these potential applications of this
method can be used with respect to studying dynamics of NKCC2 endocytosis in further
detail and can be extended to other trans-membrane proteins.
Discovering novel proteins involved in NKCC2 endocytosis
Despite the availability of novel technologies and the importance of studying
NKCC2 endocytosis, not much is known about the protein-protein interactions that are
involved in this process. So far only one protein MALVIP/17 has been characterized
and shown to regulate NKCC2 internalization [49] by interacting with a 71 amino acid
stretch of carboxyl-terminus domain of NKCC2 (C2-NKCC2). In order to discover new
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proteins that may play a role in NKCC2 internalization, we followed a targeted
proteomics approach and identified ALMS1 as an interacting partner of C2-NKCC2.
The genetic association of obesity, salt-sensitive hypertension with ALMS1 [50-53,5661], its cellular role in trafficking of membrane protein [69] and its interaction with
proteins in the endocytic pathway [66] is well described. Therefore, we hypothesized
that ALMS1 interacts with NKCC2 and stimulates its endocytosis to maintain NKCC2
surface expression and NKCC2-mediated NaCl reabsorption and therefore maintain
normal blood pressure.
ALMS1 interacts with NKCC2 and forms a network with endocytic proteins
ALMS1 is involved in trafficking of membrane transporters such as GLUT4.
Although it is unclear whether ALMS1 regulates insulin stimulated GLUT4 endocytosis
or recycling [69], the carboxyl terminus of ALMS1 interacts with proteins that form the
endocytic machinery (α-actinin 4, Myosin Vb, RINT1 etc.) [66,70-73]. C2-NKCC2 is a
71 amino acid domain in carboxyl-terminus of NKCC2 which is shown to be important
for apical targeting of NKCC2 [81]. Liquid chromatography and mass spectrometric
analysis of C2-NKCC2 interactome revealed the presence of unique peptides
corresponding to ALMS1. We found that ALMS1 is expressed along the nephron but
appears to be enriched in the TAL where it interacts with the carboxyl terminus of the
apical Na+/K+/2Cl- co-transporter, NKCC2. We found that ALMS1 co-localizes with
NKCC2 in sub-apical regions of TAL while Ingenuity pathway network analysis of CALMS1 and C2-NKCC2 interacting proteins show that ALMS1 may form a network with
RABEP1 and other Ras-related proteins (RAB5A, RAB22A; data not shown) in the TAL
and thus may be involved in the early endocytic pathway of NKCC2 [118,119]. We
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propose that ALMS1 may act as a scaffolding protein to recruit proteins involved in
NKCC2 early endocytic pathway. It is important to note that ALMS1 may not directly
interact with NKCC2 but form a complex network with other endocytic proteins, pulled
down with C-ALMS1 (Table 2).
Table 2: C-ALMS1 interacting proteins and their role in the regulation of
endocytosis
C-ALMS1 interacting proteins

Role in regulating
endocytosis

RAC1: Ras-related C3 botulinum toxin substrate 1

See Ref (160)

FLOT 1: Flotillin 1

See Ref (161)

FLOT 2: Flotillin 2

See Ref (162)

ANXA 2: Annexin A2

See Ref (163)

ANXA 1: Annexin A1

See Ref (164)

PICALM: Phosphatidyl inositol binding
clathrin assembly protein

See Ref (165)

ARPC5L: Actin related protein 2/3 complex, subunit 5-like

See Ref (166)

RALA: Ras like proto-oncogene A

See Ref (167)

ARF 1: ADP ribosylation factor 1

See Ref (168)

ILK: Integrin linked kinase

See Ref (169)

PHB: Prohibitin

See Ref (170)

ACTN 4: α-actinin 4

See Ref (171)

MYO5B: Myosin 5b

See Ref (172)

NKCC2 is known to undergo endocytosis in a clathrin and lipid-raft dependent
manner to maintain NKCC2 surface levels [38]. In this study, we show that ALMS1
mediates NKCC2 endocytosis and also identified some proteins that may form NKCC2
endocytic protein network. With carboxyl-terminus of ALMS1 (C-ALMS1), we pulled
down flotillin-2 (FLOT2) which is a lipid raft marker protein.

We also pulled down

Annexin A2 (ANXA2) which has been shown to be important for lipid raft-associated
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apical trafficking of NKCC2 [120]. This suggested that ALMS1 may be involved in lipid
raft-dependent NKCC2 endocytosis. We also pulled down phosphatidylinositol binding
clathrin assembly protein (PICALM) with C-ALMS1, which has been shown to mediate
clathrin-dependent endocytosis and targeting of clathrin-coated vesicles to early and
late endosomes of other proteins [121]. This suggests the role of ALMS1 as a common
scaffold to recruit various proteins involved in determining lipid raft and/or clathrin
dependent NKCC2 endocytosis. While this question remains to be answered, ingenuity
pathway network analysis of C-ALMS1 interacting proteins, suggest a role for ALMS1 in
mediating membrane protein endocytosis.
ALMS1 stimulates NKCC2 endocytosis, a mechanism to maintain NKCC2 surface
levels in the TAL
In this study, we show that ALMS1 interacts with C2-NKCC2 and stimulates
NKCC2 internalization in the TAL such that genetic deletion of ALMS1 decreases
NKCC2 internalization only after 20 min of warming TALs at 37ºC to facilitate
constitutive NKCC2 endocytosis but not at 10 min time point. Since NKCC2 is known to
undergo endocytosis via clathrin-dependent and lipid-raft dependent pathways [38], it is
possible that these pathways differentially participate at distinct time points during
constitutive NKCC2 internalization in TALs. While it is still debatable as to which one of
these pathways does ALMS1 play a role in, inhibition of ALMS1 expression may
significantly retard either one of these pathways that appears to be active during the
latter 10 minutes. This may result in a significant difference in NKCC2 internalization in
TALs from WT and ALMS1 KO rats only after 20 minutes of allowing NKCC2
endocytosis. In addition, we demonstrated that a decrease in NKCC2 endocytosis
correlated with higher surface NKCC2 in TALs from ALMS1 KO rats.
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A previous study had shown that another protein MAL/VIP17 interacts with this
domain in NKCC2 in LLC-PK1 cell lines and decreases NKCC2 internalization via
NKCC2 retention at the surface. This suggests that C2-NKCC2 may be an important
regulatory domain involved in modulating NKCC2 surface expression mediated via
specific protein-protein interactions.

MAL/VIP17-overexpressing transgenic mice

presented only with an increase in NKCC2 phosphorylation and NKCC2 glycosylation
indicative of stable surface expression. This observation was not accompanied by any
report on renal ion transport phenotype in these mice [49]. In the present study, we
show that deletion of NKCC2 interacting protein ALMS1 in rats presents with high
NKCC2 surface expression accompanied with a phenotype related to higher renal
tubular Na+ reabsorption.

Since NKCC2 activity is also known to be stimulated by

phosphorylation [29], we measured this using specific antibodies against pThr(96,101)
or pSer(126) NKCC2 and found no difference in NKCC2 phosphorylation between the
groups. This shows that ALMS1 is not involved in regulating NKCC2 phosphorylation
but primarily involved in regulating NKCC2 endocytosis.
ALMS1 regulates NKCC2-mediated NaCl reabsorption and therefore blood
pressure
The thick ascending limb (TAL) of the loop of Henle plays an important role in
maintenance of NaCl homeostasis and blood pressure regulation [30,31].

NaCl

reabsorption by this nephron segment is dependent on the apical Na+/K+/2Cl- cotransporter NKCC2.

In spontaneously hypertensive rats, progression from pre-

hypertensive to hypertensive state is accompanied by an increased surface NKCC2
expression compared with control rats [122]. Dahl salt-sensitive rats exhibited higher
surface NKCC2 expression and NKCC2 activity in TALs compared to Dahl salt-resistant
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rats [123]. This indicates that a higher NaCl reabsorption in the TAL is associated with
elevated arterial pressure and salt sensitivity.

Our data suggest that knockout of

ALMS1 in rats leads to elevated blood pressure and salt sensitivity possibly via this
mechanism since diuretic and natriuretic response to bumetanide was increased in
ALMS1 KO rats.

Bumetanide inhibits NKCC2 activity which leads to a decreased

interstitial osmolarity and thus decreased water reabsorption in the collecting duct [124].
A sub-maximal dose of bumetanide (5 mg/kg) was used to detect subtle differences in
bumetanide sensitivity between the groups. Increased urinary concentrating ability of
ALMS1 KO rats may be in part due to higher NKCC2-mediated NaCl reabsorption
leading to increased medullary interstitial osmolarity and secondarily causing enhanced
water reabsorption in the cortical collecting duct via aquaporins. However, it is possible
that ALMS1 may also be primarily involved in apical trafficking of aquaporins and
thereby regulating water reabsorption in collecting duct principal cells. Together, these
data indicate that a higher NKCC2-mediated NaCl reabsorption in the TAL contributes
at least in part to the hypertension and salt-sensitivity in ALMS1 KO rats. In addition,
plasma renin activity (PRA) is lower in ALMS1 KO rats despite the collection method
used which has been reported to cause abnormal increase in PRA by anesthesia or by
renal baroreflex [125], suggesting that hypertension is independent of renin-angiotensin
system. These data together suggest that salt sensitive hypertension in ALMS1 KO rats
is predominantly due to a higher renal tubular NaCl reabsorption which probably causes
a rightward shift in the pressure natriuresis curve in order to maintain sodium balance
[27,122,132].
It is worth nothing that baseline GFR in hypertensive ALMS1 KO rats is similar to
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WT rats however baseline renal blood flow (RBF) in ALMS1 KO rats tended to be
slightly lower although not significantly different from WT rats (ALMS1 KO: 7.6 ± 0.65
ml/min/gkw, n = 5 vs. WT: 6.55 ± 0.63 ml/min/gkw, n = 6). This GFR auto-regulation as
seen in other models [128-131] has been implicated to be predominantly due to
enhanced myogenic response of preglomerular arterioles [126,127] and tubuloglomerular feedback (TGF) [133-136].

We observed an increased renal vascular

resistance (RVR) in ALMS1 KO rats (ALMS1 KO: 28.7 ± 2.3 mmHg/ml/min/gkw vs. WT:
16.5 ± 0.9 mmHg/ml/min/gkw, n = 5, * p < 0.05) and this may be a mechanism to protect
the kidney from elevations in arterial pressures to be transmitted to the glomerular
capillaries and cause injury. While the underlying mechanism of GFR autoregulation in
ALMS1 KO rats is unknown, understanding the contributing role of TGF is important.
Decreased Cl- delivery to the macula densa in ALMS1 KO rats due to higher TAL NaCl
reabsorption may tend to decrease TGF activity [133-136]. While increased NKCC2mediated NaCl reabsorption at the macula densa in ALMS1 KO rats may tend to
increase TGF activity [133-136]. Thus, under mutually opposing conditions, examining
baseline TGF responses in ALMS1 KO rats may offer new insights into understanding
its mechanism. Upon 3% volume expansion, GFR in WT rats increased whereas it
remained relatively unchanged in ALMS1 KO rats (data not shown). This may indicate
TGF resetting in WT rats which seems to be absent in ALMS1 KO rats to facilitate
elimination of salt/water load [133-136]. This phenomenon of TGF resetting may in part
explain faster volume/salt load excretion in WT rats compared to ALMS1 KO rats.
Association of ALMS1 gene locus to renal function and hypertension
Single nucleotide polymorphisms in the ALMS1 gene have been associated with
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hypertension, pulse pressure and pulse rate in a multipoint linkage analysis in primary
sibling samples of African American, Caucasian and Mexican populations [56]. Several
quantitative trait loci for salt sensitivity are associated with the ALMS1 gene locus [5761]. Two independent GWAS [62,63] found genetic variants in ALMS1 associated with
kidney function and one study associated SNPs in the ALMS1 locus to hypertension
and increased pulse pressure [4]. The same GWAS [62] along with studies by other
independent consortia [90-94] found susceptibility variants in uromodulin (UMOD,
Tamm-Horsfall protein), a protein expressed in the TAL, to be associated with
decreased renal function and hypertension.

A functional link between NKCC2 and

UMOD was established showing that UMOD plays a role in blood pressure regulation
and salt sensitivity via regulating NKCC2 activity [95]. While the molecular function of
UMOD has been well studied, it is not known whether ALMS1 and UMOD interact. We
did not pull down UMOD with GST-C-ALMS1 A/B, suggesting that UMOD may interact
with some other region of ALMS1 or may be independently linked to renal function
through regulation of NKCC2 activity rather than interacting with each other.
Nonetheless, mutations in ALMS1, similar to UMOD contribute to hypertension and may
serve as a biomarker or a therapeutic target for lowering blood pressure and preserving
renal function.
Hypertension is a complex polygenic disease in which multiple genes contribute
to alter multiple organ function to elevate blood pressure. Our current understanding of
the complex genetic architecture of hypertension relies heavily on the identification of
mutations causing rare inherited disorders and of several susceptibility loci through
population-based association studies. Such studies have allowed us to identify genetic
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regions associated with hypertension, its complications like renal dysfunction, chronic
kidney disease (CKD) [137,138] among others. Given the existing GWAS data linking
SNPs in ALMS1 with decreased renal function, and the severe phenotype observed in
Alström syndrome patients [50-53], our data provides the first evidence that ALMS1 is
involved in the regulation of renal sodium transport and therefore blood pressure
regulation such that ALMS1 KO rats are hypertensive and have decreased ability to
excrete a volume load. The mechanism for this defect involves decreased NKCC2
endocytosis, which causes accumulation of NKCC2 at the apical surface and higher
TAL NaCl transport. ALMS1 was not exclusively located in the TAL, suggesting that it
may also regulate endocytosis of other renal sodium transporters. Our data is the first
to suggest that enhanced tubular NaCl reabsorption and hypertension may be involved
in progressively decreasing renal function in patients with decreased ALMS1
function/expression.

Figure 36: Working model for cellular role of ALMS1 in the regulation of NKCC2 endocytosis in the
thick ascending limb.
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Based on our observations, we propose the model depicted in Figure 36.
ALMS1 interacts with NKCC2 in the sub-apical regions in the TAL and may be
involved in its early endocytic pathway as a scaffold protein to recruit other endocytic
proteins to facilitate NKCC2 endocytosis.

Regulation of NKCC2 endocytosis is

important for maintaining normal NKCC2 surface expression and NKCC2-mediated
NaCl reabsorption which contributes to maintenance of normal blood pressure.
Splice variants and isoforms of NKCC2 and their interaction with ALMS1
Although NKCC2 is encoded by a single gene (Slc12a1), differential splicing of
NKCC2 mRNA results in three splice variants - NKCC2 A, B and F due to the variable
exon 4. These isoforms differ in their localization along the TAL, macula densa and in
their affinity for Cl- ion [158]. Since the amino acid changes in these variants are
located in one of the intracellular transmembrane loop closer to the N-terminus, it is
very likely that the interaction of ALMS1 with C2-NKCC2 is conserved across the
isoforms. Additionally, NKCC2 B isoform is primarily expressed in the macula densa
and thus, ALMS1 via its interaction with NKCC2, may potentially play a role in
regulating TGF.
NKCC1 is a very closely related member to NKCC2, belonging to the cationchloride co-transporter family.

Despite sharing 60% homology with NKCC2, C2-

NKCC2 region that interacts with ALMS1 is not conserved between the isoforms as
depicted by highlighted residues in Figure 37. Additionally, phenylephrine which is
known to stimulate vascular contractility by enhanced NKCC1 phosphorylation and
activity [159], induced similar vasoconstrictor response in abdominal and thoracic
aorta from 6-10 week old WT and ALMS1 KO rats (Figure 38). These data together
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suggest that ALMS1 is likely not an interacting partner of NKCC1 and therefore may
not regulate its membrane trafficking and activity.

Figure 37: Alignment of C2-NKCC2 and corresponding protein sequence in NKCC1.

ALMS1 KO rats have normal cilia
In some cells, ALMS1 is known to be involved in ciliary function.

A study

demonstrated that knockdown of ALMS1 in mouse inner medullary collecting duct
(mIMCD3) cell line caused defective ciliogenesis [89], indicating a role for ALMS1 in the
maintenance of ciliary function. In contrast, cilia appeared to assemble normally in renal
collecting tubules from ALMS1 transgenic mice [67]. Similarly, fibroblasts from human
Alström syndrome patients were shown to have normal cilia but had defects in
membrane trafficking [66], indicating that the pathology observed in these patients may
be due to defects in intracellular trafficking. While the role of ALMS1 in ciliary function is
debatable, our data suggest that ALMS1 KO rats seem to have normal ciliary
development in the renal tubules indicating that the renal phenotype observed in
ALMS1 KO may be independent of cilia. However, it has to be noted that we only
measured cilia length but not ciliary function in WT and ALMS1 KO rats. Despite cilia
appearing normal in length and number, it is possible that ciliary function such as flowinduced nitric oxide synthesis etc. may be affected in ALMS1 KO rats. However, it is
unlikely that other cilia-mediated signaling in response to flow stimulus that are
associated with development of cysts are affected because the kidneys (n = 9) from 7
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month old (oldest surviving) ALMS1 KO rats do not appear polycystic.

Figure 38: Phenylephrine-induced vasoconstriction is similar in abdominal (AA) and thoracic (TA)
aorta from ALMS1 KO and WT rats, N = 3.

ALMS1 and metabolic syndrome
Little is known about the function of ALMS1 in other organs. ALMS1 seems to be
involved in the development of obesity, since Alström syndrome patients develop early
onset obesity and ALMS1 targeted mutations in mice leads to the development of age
dependent obesity, insulin resistance, diabetes and hepatic steatosis between the ages
of 18 to 21 weeks [67]. In our study to measure renal function and blood pressure, we
used young adult rats between the age of 6 to 12 weeks to avoid the potential effect of
other confounding factors on the measurement of blood pressure and renal function. At
this age, body weight was slightly higher in ALMS1 KO but metabolic parameters were
normal (Table 1). ALMS1 may be involved in the development of insulin resistance
through the regulation of insulin-stimulated GLUT4 trafficking. At the age we studied
our rats (6 to 12 weeks), they had normal plasma glucose and insulin. However, we
hypothesized that ALMS1 KO rats will develop metabolic syndrome as they age.
ALMS1 is required to maintain normal metabolic function in rats
Metabolic syndrome is known as a clustering of cardiovascular risk factors
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associated

with

hypertension,

insulin

resistance,

glucose

intolerance,

hypertriglyceridemia and low levels of high-density lipoprotein (HDL). Several genetic
loci have been discovered that are individually associated with a few of the above
mentioned risk factors. In humans, inactivating mutations in the ALMS1 gene causes
Alström syndrome which is characterized by cardiomyopathy, diabetes mellitus, obesity
and hypertension.

Both sexes of the ALMS1 mutant mice recapitulated metabolic

syndrome as seen in Alström patients while some sex-differences were observed [67].
However, loss of ALMS1 in mice was not characterized for hypertension or renal
function.

To understand the underlying integrated mechanism of hypertension and

associated etiologies in both sexes, we generated an ALMS1 KO rat model by zinc
finger nuclease gene targeting of exon 1 of the ALMS1 gene. In this study we show that
ALMS1 KO rats are a model of metabolic syndrome including hypertension. Elevated
blood pressure preceded other characteristics of metabolic dysfunction in these rats.
Additionally, female ALMS1 KO rats exhibited a more severe form of metabolic
syndrome compared to their male counterparts.
differences is unknown.

The underlying cause of sex-

However, we found that C-ALMS1 interacts with proteins

involved in estrogen receptor signaling such as prohibitin 2 and KRAS protooncogene
(data not shown) and this may be a potential hypothesis that requires further testing.
Role of ALMS1 in development of insulin resistance
ALMS1 mutant mice displayed altered intracellular localization of GLUT4 and
decreased insulin-stimulated trafficking of GLUT4 to the plasma membrane in
adipocytes [69]. Thus, ALMS1 may be involved in the development of insulin resistance
through the regulation of insulin-stimulated GLUT4 trafficking.

However, caloric
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restriction in an Alström patient prevented hyperinsulinemia [139] indicating
hyperinsulinemia may develop secondary to obesity. In foz/foz, a mouse strain carrying
mutation in ALMS1, it was found that along with hyperphagia, impaired brown adipose
tissue (BAT) diet-induced thermogenesis is an important factor driving diet-induced
obesity and glucose intolerance [140].

Additionally, stable knockdown of ALMS1 in

3T3-L1 preadipocytes was associated with impairment of lipid accumulation and a
twofold reduction in adipocyte gene expression following hormonal induction of
adipogenesis [141], suggesting that partial impairment of early phase adipogenesis in
Alström syndrome may contribute to the severity of the associated metabolic phenotype
[141,142]. In contrast, pre-adipocytes isolated from ALMS1 mutant mice demonstrated
normal adipogenic differentiation but gave rise to mature adipocytes with reduced
insulin-stimulated glucose uptake. Reduced insulin-stimulated GLUT4 translocation to
the plasma membrane in adipose depots may serve as a potential explanation for
glucose intolerance and the compensatory hyperinsulinemia. Thus adipose tissue with
a reduced glucose uptake can expand by de novo lipogenesis to an obese state [69].
Role of ALMS1 in development of obesity
In hypothalamic neurons, ALMS1 is known to be present in the base of the cilia,
known to play a role in the control of satiety. In foz/ foz mice, loss of ALMS1 from this
location coincided with a reduction in adenylyl cyclase 3 (AC3), a signaling protein
implicated in obesity, suggesting the role of ALMS1 in neuronal ciliary function [143].
However, we found that ALMS1 KO rats have normal circulating leptin before any
difference in body weight was be detected (data not shown).

Thus it is debatable

whether hyperleptinemia develops secondary to obesity due to a role of ALMS1 in
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neuronal cilia or primarily due to a role of ALMS1 in leptin receptor signaling and this
requires further examination.
In summary, ALMS1 KO rat model provide an appropriate tool to elucidate the
associated pathophysiological mechanisms of metabolic dysfunction and cardiovascular
risk factors.
Strengths and limitations of the study
Strengths: We performed most of our work in native TALs or in primary culture of
TALs which retain native cellular characteristics compared to commercial cell lines. We
utilized in vivo silencing techniques via ALMS1 shRNA adenoviral transduction into
outer renal medulla in rats. We also took advantage of global knockout animal models
for testing our hypothesis.

We consider that these approaches enhance the

significance of our findings and increase the translational relevance of the mechanisms
elucidated to human physiology.
Limitations: Despite well conserved basic principles of cellular and renal
physiology between rodents and humans, some limitations do exist. However, the kind
of research we conducted here would have been impossible to perform in human
subjects.
Following are some specific limitations related to our study:
1. Despite only labeling surface NKCC2 for live-cell imaging and monitoring its
endocytosis by TIRF, visualization of other NKCC2 trafficking events such as recycling
is possible. However, these events will be extremely rare over 20 minutes of live cell
imaging because constitutive NKCC2 recycling in rat TALs becomes significant only
about 40 minutes after warming the TAL at 37 ºC to allow internalization.
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2. Our experiments were performed in medullary TAL suspensions that are
enriched from whole outer renal medullary suspensions and thus are not completely
pure. Despite this limitation, the fact that NKCC2 is only expressed in TALs makes the
contamination of other nephron segments in medullary TAL suspensions less relevant.
However, this is not applicable to ALMS1 which is expressed in other outer renal
medullary tubules and thus >90% TALs in the enriched suspension or a standardized
TAL enrichment protocol across all sample groups is an acceptable representative
sample for comparing protein expression.
3. The studies performed in TAL primary cell culture are not best representative
of native cellular physiology as they grow under controlled laboratory conditions which
do not mimic native conditions and is devoid of complex confounding environment found
in vivo
4. The GST pull down studies enabled us to identify that ALMS1 interacts with
NKCC2 but does not help us determine whether this interaction is direct or via
intermediate proteins, since these proteins could precipitate as part of a larger protein
complex.
5. ALMS1 is very likely involved in trafficking of other plasma membrane proteins
which could have an indirect effect on NKCC2 endocytosis in TAL and thereby affect
blood pressure. However, we found a direct evidence of interaction and co-localization
between ALMS1 and NKCC2 in TAL, suggesting they are very likely to play a direct
role. By no means is this an indication that such a role is exclusive for NKCC2 and
certainly not a way we formulated our hypothesis and interpreted our results. It is very
likely that ALMS1 is involved in trafficking of other renal transporters like NHE3, ROMK,
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NCC, ENaC etc. which may possibly explain the mechanism underlying higher blood
pressure in ALMS1 KO rats but testing this hypothesis goes beyond the scope of this
study.
We consider testing whether ALMS1 mediates trafficking of other proteins in the
TAL, a mechanism which could in turn affect NKCC2 endocytosis indirectly. However,
this is a separate hypothesis and requires a different experimental design.
6. We measured renal function and blood pressure in global ALMS1 knockout
rats. In order to address whether ALMS1 expressed specifically in the TAL mediates the
effects we observed, a different model of TAL or renal tubule (Pax8)- targeted ALMS1
deletion is necessary. Although we believe our studies provide the first observation that
ALMS1 is important for renal function and blood pressure regulation, this does not mean
ALMS1 in the TAL is exclusively responsible for the effects we found.
7. The ALMS1 KO rats were obtained from MCW and were generated on a Dahl
salt sensitive (SS) background. Since Dahl SS rats are known to be salt sensitive, we
can only measure whether genetic deletion of ALMS1 in these rats exacerbates salt
sensitivity. However, a previously characterized ALMS1 mutant mouse model bred on a
C57/Bl6J background were not available for our research and studying trafficking with
murine tissue would be very cumbersome.
8. Zinc finger nuclease gene editing technology has been known to have several
off-target effects. With the exception of blood pressure and renal phenotype, some of
the metabolic characteristics observed in the ALMS1 KO rats have been previously
reported in a different ALMS1 transgenic mouse model indicating these effects may be
due to ALMS1 specific deletion in the current rat model and not due to off-target effects.
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Perspectives
About 35% of Americans are hypertensive [144] which incur huge healthcare
costs and lost productivity thereby affecting the economy [145].

Hypertension is

associated with an increased risk of left ventricular hypertrophy, a risk factor for
cardiovascular death. Coexistence of hypertension and diabetes mellitus triples the risk
for cardiovascular disease as indicated in Framingham Heart study [146] and MRFIT
trials [147]. Obesity-related hypertension is also known to predispose to coronary heart
disease, renal dysfunction, left ventricular hypertrophy and congestive heart failure
[148-151]. Presence of hypertension in the setting of obesity and diabetes create a
viscious feed-forward loop that also increases the occurrence of end-stage kidney
failure [152].
The kidneys reduce extracellular fluid volume by enhancing sodium and water
excretion in response to increased arterial pressure [153], thus playing a crucial role in
maintaining blood pressure.

In this dissertation we have described a molecular

mechanism that regulates NKCC2 endocytosis, a key pathway that maintains normal
surface NKCC2 expression and activity in the TAL, a nephron segment that has a
substantial influence over blood pressure regulation.
Here we propose a mechanism that regulates NKCC2 surface expression via
interaction with ALMS1. According to Rat Genome Database, ALMS1 (chromosome 4)
genetically overlaps with several quantitative trait loci (QTL) in hypertensive strains and
has been associated with hypertension and renal function in several genome wide
association studies. Our study is the first to show the role of ALMS1 in regulating
NKCC2-mediated NaCl reabsorption and thereby blood pressure and propose that this
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mechanism may be involved in progressively decreasing renal function in patients with
decreased ALMS1 expression and/or function.

Furthermore, ALMS1 mutations in

humans causes Alström syndrome characterized by age-dependent metabolic
dysfunction. Elucidation of new genes that are involved in regulation of NKCC2 activity
and metabolic function could lead the way to identifying potential biomarkers and
understanding the interacting mechanisms of hypertension and metabolic syndrome
which are known to increase the risk for cardiovascular and renal disease.
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CHAPTER 6 - GENERAL METHODS
Animals
In vivo transduction of ALMS1 shRNA in the outer medulla was performed in 90110g male Sprague Dawley rats (Charles River Breeding Laboratories, Wilmington, MA)
as reported previously [88].

ALMS1 KO rats were generated in Dahl salt-sensitive

background and were males of 6-12, males and females of 16-18 weeks of age. Age
matched littermate controls were male and female Dahl salt-sensitive rats respectively.
Animals were fed a standard diet (0.22% Na, 1% K) from Envigo (Indianapolis, IN). All
procedures involving live animals were approved by the Institutional Animal Care and
Use committee (IACUC) of the Henry Ford Hospital and conducted following guidelines.
Generation of ALMS1 KO rats
Frame shift deletion of 17 bp in exon 1 (containing a Nci1 restriction site) of
ALMS1 gene was facilitated by injecting zinc Finger nucleases targeting the sequence
CCCGCCTCCGACTCCGCCtccgtcCTCCCGGCACCAGTA into Dahl SS/JrHsdMcwi rat
embryos. This deletion caused a fame shift leading to a pre-mature stop codon in exon
2. Confirmation of deletion was done by PCR using exon 1 specific primers:
Forward primer- AGAGGAAGAGTTGGAAGGGG,
Reverse primer- ATACATAGGCAGAGCGACCC
followed by Nci1 restriction digestion.
Antibody and reagents
The anti-NKCC2 antibody was generated in rabbit against a carboxy-terminal
sequence as described before [35,37]. pThr (96/101) NKCC2 and pSer (126) NKCC2
antibodies were used as previously described [29,88]. Antibodies against carboxylterminus ALMS1 was generated in rabbit and was obtained from Dr. Jürgen Naggert
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[66). Another ALMS1 antibody was generated against a short peptide epitope in the Cterminus of ALMS1: CEARLEEDSDVTSSSEEKAKE (similar to antibody obtained from
Dr. Naggert) [66]. Another ALMS1 antibody was generated against amino acids (21742296) of mouse ALMS1 (Genscript Inc., Piscataway, NJ).

Reagents for surface

biotinylation were from Thermo Fisher scientific (Waltham, MA) and for GST-pull down
were from GE Life Sciences. Bumetanide was purchased from Sigma Aldrich.
Constructs and plasmids
The eGFP-NKCC2 (mouse) construct was provided by Dr. Gerardo Gamba,
Universidad Nacional Autonoma de Mexico, Mexico [154]. eGFP-NKCC2 was subcloned from pSPORT1 into VQAd5CMV adenovirus plasmid vector (ViraQuest, North
Liberty, IA) between ApeI and NotI restriction sites. cMyc-NKCC2 (rat) sequence
(accession number U10096.1) was commercially synthesized by Genscript (Piscataway,
NJ) and was sub-cloned into VQAd5CMV adenovirus vector between KpnI and NotI
restriction sites. XbaI restriction site was introduced by site directed mutagenesis in the
extracellular loop between the 5th and 6th trans-membrane domains of NKCC2. The
XbaI site was used to introduce the Biotin Acceptor Domain (BAD) derived from
Propionibacterium shermanii [74,75,79] to generate VQAd5CMV-cMyc-NKCC2-BAD
adenoviral construct. The ss-BirA (secretory sequence- BirA)-IRES-mCherry construct
consists of a biotin ligase fused to yolk sac secretory sequence which targets proteins
for secretory pathway [75,79].

It was sub-cloned from CSCW lentiviral vector to

VQAd5CMV between BamHI and XbaI restriction sites resulting in the VQAd5CMVssBirA adenoviral construct. All clones were fully sequenced and adenoviral particles
were assembled and purified by ViraQuest Inc (North Liberty, IA).
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MDCK cell culture
Mardin- Darby Canine Kidney (MDCK) Type-2 cell were obtained from American
Type Culture Collection (ATCC, Rockville, MD).

Cells were cultured in Dulbecco’s

modified Eagle’s medium (DMEM-high glucose, HEPES, no phenol red) (Life
Technologies, Grand Island, NY) supplemented with 5 % heat inactivated fetal bovine
serum (FBS) (Life Technologies), and Penicillin- Streptomycin mix (Life Technologies).
Cells were seeded in collagen-coated Trans-well permeable support (Corning,
Tewksbury, MA) and incubated for 3 days at 37ºC and 5% CO2 until 90% confluent.
Primary culture of rat TALs
Primary culture of rat TAL was done as previously described [88] following
institutional and national guidelines for the care and use of laboratory animals. All
protocols involving animals were approved by the IACUC at the Henry Ford Hospital.
Sprague-Dawley rats weighing 100-120 g were used. Kidneys were perfused with 0.1%
collagenase (Sigma, St. Louis, MO) and the outer medulla was dissected. Individual
TAL cells were obtained from TAL suspensions after digesting the tubules with 0.1%
collagenase, 0.25% trypsin (Sigma) and 0.0021% DNase (Sigma). Single TAL cells
were isolated by density gradient centrifugation in 35% Percoll (Sigma) washed and
seeded in permeable supports (Corning, Tewksbury, MA) coated with basement
membrane extract (Trevigen, Gaithersburg, MD). Cells were grown for 4 days in DMEM
(Low glucose, no phenol red, no glutamine) supplemented with 1% FBS, PenicillinStreptomycin mix and Insulin-Transferrin-Selenium (Life Technologies) at 37ºC and 5%
CO2 until 90% confluent.
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Transduction of polarized cells
Cells were transduced by adding adenoviruses at 1x108 Plaque Forming Units
(PFU) per ml suspended in serum-free DMEM and added to the basolateral
compartment of the transwells. 2 hours after viral transduction, serum was added to
inactivate viruses and the cells were incubated at 37ºC for 20 -24 hours.
Suspensions of medullary TALs
TAL suspensions were obtained as described previously. Animals were
anesthetized with ketamine and xylazine mixture i.p. and kidneys perfused via the
descending aorta with 0.001% collagenase. Kidneys were harvested, the outer medulla
was dissected and digested in 0.1% collagenase at 37ºC for 30 minutes with
oxygenation every 5 minutes followed by mechanical stirring on ice for 30 minutes. The
suspension was then filtered through a 250 um nylon mesh.
Steady-state surface biotinylation
Steady-state surface NKCC2 was measured in suspensions of TALs as
described previously [37]. TALs were biotinylated at 4ºC with NHS-SS-biotin (0.9 mg/ml)
and then washed and lysed.

Extracted proteins were incubated with steptavidin-

agarose beads (Pierce Biotechnology) at 4ºC overnight to separate the biotinylated
protein fraction (surface protein fraction) from the non-biotinylated protein fraction
(intracellular protein fraction). Beads were washed and proteins were extracted from
beads by warming at 37ºC. Proteins were resolved by SDS-PAGE (6% gels). NKCC2
and GAPDH were detected by Western blot. Surface NKCC2 was calculated as a
percentage of total NKCC2 (sum of surface and intracellular NKCC2 fraction).
For surface biotinylation in MDCK cells, it was performed using NHS-SS-biotin by
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a method that we described previously in primary cultures of rat TAL suspension [88].
In order to confirm correct targeting of eGFP-NKCC2 construct to apical surface and
absence of targeting to the basolateral surface, we performed apical and basolateral
surface biotinylation. Cells were biotinylated at 4ºC with NHS-SS-biotin (0.9 mg/ml)
added either in the apical or basolateral compartment of the transwells. To prevent
access of NHS-SS-biotin to the apical surface from the basolateral compartment during
basolateral surface biotinylation or vice versa, MDCK cells were pre-treated with NHSacetate (2 mg/ml) for 1 hour at 4ºC added to either the apical or basolateral
compartment of the transwell to mask lysine biotinylation sites [36] prior to the addition
of NHS-SS-biotin. Cells were washed and lysed in buffer containing 150 mM NaCl, 50
mM HEPES (pH 7.5), 5 mM EDTA, 1% Triton X-100, 0.2% SDS and protease inhibitors.
Extracted

proteins

were

incubated

with

streptavidin-agarose

beads

(Pierce

Biotechnology) at 4ºC overnight. Beads were washed and biotinylated proteins were
extracted by boiling in 60 µl SDS-loading buffer containing 100 mM dithiothreitol and 5%
β-mercaptoethanol.

Proteins extracted from the beads (surface) and supernatant

(intracellular) were resolved by SDS-PAGE (6% gels). NKCC2 and GAPDH were
detected by Western blot.
Site-specific NKCC2 biotinylation and streptavidin Alexa Fluor-488 labeling
Cells transduced to express NKCC2-BAD were serum starved for 2 hours at
37ºC and then treated with or without 5 mM Methyl-β-cyclodextrin (MβCD) (Sigma) in
serum-free DMEM for 20 minutes. Cells were then washed with PBS containing 0.1
mM CaCl2 and 4 mM MgCl2 (PBS-Ca-Mg) pH 7.6. Cells were incubated with 5% BSA in
PBS-Ca-Mg (pH 7.6) for 20 minutes to block non-specific binding reactions in the
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following steps.

To allow biochemical biotinylation of BAD-NKCC2, a solution

containing 10 µM d-biotin (Avidity, Aurora, CO), 2 mM ATP and 0.53 µM biotin ligase
(BirA) (Avidity, Aurora, CO) in PBS-Ca-Mg was added to the extracellular apical bath
and incubated for 20 minutes at room temperature. VQAd5CMV-ssBirA adenovirus
construct was co-transduced with NKCC2-BAD to facilitate metabolic biotinylation.
Unreacted biotin was removed by cooling the cells to 4ºC and briefly washing with
chilled PBS-Ca-Mg (pH 7.6) and then with PBS-Ca-Mg (pH 3.0). Alexa Fluor 488conjugated streptavidin (Life Technologies) was added to the apical bath at 1:400
dilution in 5% BSA/ PBS-Ca-Mg (pH 7.6, 4ºC). Finally, multiple washes were done to
remove unbound streptavidin with PBS-Ca-Mg at pH-7.6 and 3.0.
Apical total internal reflection fluorescence (TIRF) microscopy
The membranes in the Trans-well were carefully cut and separated from the
inserts, and placed in a temperature-controlled chamber at 37ºC facing down, such that
the apical surface faced the objective lens. Cells were covered with a 0.13-0.17 mm
thick glass coverslip (Fisher Scientific, Waltham, MA) and transferred to an inverted
scope (Nikon TE2000U), equipped with “through the lens” TIRF module, 100x 1.45 NA
TIRF lens (Nikon), in a way that the apical membranes faced the objective lens. A blunt
glass pipette mounted on micromanipulators was lowered on the membrane from the
basolateral side to push the apical membranes down and closer to the glass coverslip.
Prior to imaging, serum-free DMEM was added to the basolateral side of the chamber
and cells were allowed to equilibrate at 37ºC for 10 min. A region of interest was
selected and the 488 nm excitation laser was angled until reflection was observed on
the glass coverslip.

To observe and measure real-time endocytosis, images were
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acquired continuously once per second. Images were captured and acquired once per
minute at 1000 millisecond frame rate for twenty minutes. Images were acquired at
1024x1024 pixel resolution with an EM-enhanced cooled CCD (Photometrics Cascade
II 1024 EMCCD).

Each image was deconvolved using AutoQuant software (Media

Cybernetics, Rockville, MD) and analyzed with Metamorph® software (Molecular
Devices, Sunnyvale, CA).

The Granularity module of Metamorph was used to

automatically count the number of puncta (singular- punctum) present on the TIRF field
over time. Background fluorescence intensity was measured from a region on TIRF field
with no punctum.
Endocytosis assay of NKCC2 in TALs
NKCC2 endocytosis was measured as described previously [37,38]. TALs were
biotinylated at 4ºC. Suspension was split in four and the last 3 fractions were warmed
to 37ºC for 0, 10 and 20 minutes to allow endocytosis. The TALs were rapidly cooled to
halt protein trafficking.

TALs were then treated for 30 minutes at 4ºC with the

membrane-impermeant reducing agent MesNa (50 mM) to strip biotin from surface
proteins while protecting biotinylated proteins that internalized.

TALs from all four

fractions were then lysed and equal amounts of proteins were incubated with agarosestreptavidin to separate biotinylated proteins that internalized while the first fraction
served as baseline surface NKCC2. Proteins were then resolved by SDS-PAGE and
NKCC2 was detected by Western blot. Internalized NKCC2 was measured as a
percentage of total (100%) biotinylated surface NKCC2 fraction.
GST pull down
A GST fusion protein consisting of GST fused to the 71 amino acid domain in
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NKCC2 that is shown to be important for apical targeting of NKCC2 (GST-C2-NKCC2)
was engineered by subcloning the corresponding nucleotides in the sequence of rat
NKCC2 downstream of GST in the pGEX-6P-1 vector (GE healthcare). GST alone
construct served as the negative control. The constructs were separately transformed
by heat shock into competent E. coli and induced to express the construct by incubation
with 0.18 mM IPTG at 28ºC for 10 hours.

Bacterial proteins were extracted and

incubated with glutathione-conjugated sepharose beads (GE healthcare) to purify the
induced protein. 100 µg of rat TAL protein lysate was incubated with purified GST-C2NKCC2 and GST alone overnight at 4ºC after pre-clearing the lysate with GST alone for
1 hour. The beads were washed next day and submitted to the Proteomics Core of
Michigan State University (East Lansing, MI) for liquid chromatography and mass
spectrometry to identify C-NKCC2 interacting proteins. The resulting protein candidates
were analyzed and screened based on criteria mentioned in the results section. To
determine if C-ALMS1 binds to NKCC2, two truncated carboxyl-terminus ALMS1
constructs were obtained from Dr Jürgen Naggert.

These truncated constructs

correspond to amino acids 2683 to 2932 (referred to as C-ALMS1-B) and 2988 to 3251
(referred as C-ALMS1-A) in mouse ALMS1. These constructs were cloned downstream
of GST in pGEX-6P-1 vector while GST alone served as a negative control. Purification
of the induced proteins and GST pull down assay was performed as mentioned above.
The pull-down proteins were eluted from glutathione-conjugated sepharose beads with
6x loading buffer containing DTT and β-mercaptoethanol and resolved by SDS-PAGE.
NKCC2 was detected by Western blot.
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Histology and immunohistochemistry
Kidneys were fixed by perfusing the rats with 4% paraformaldehyde through the
abdominal aorta. The kidneys were then stored in 10% formalin for at least a day
before embedding and processing the tissue by the Biobank and Correlative Science
Core at Wayne State University (Detroit, MI). 5 µm thick sections of the kidney were
obtained for hematoxylin-eosin (H&E) and immuno-staining. For co-labeling of NKCC2
and ALMS1 in kidney sections, paraffin-embedded slices were first deparaffinized with
xylene and then hydrated gradually through 100% ethanol to distilled water.

Heat-

induced epitope retrieval was used to unmask the antigens followed by incubation with
1% BSA for 30 min to block nonspecific binding.

Slides were incubated with 1:50

dilution of NKCC2 primary antibody for 1 hour at RT. This was followed by 1:100 of
Alexa-Fluor 488 Goat anti-Rabbit IgG (Molecular probes, Eugene, OR) for 1 hours at
RT. To facilitate labeling of ALMS1, biotinylated ALMS1 antibody was prepared using
the antibody biotinylation kit (Pierce, Thermo Fisher Scientific, Waltham, MA).

The

slides were incubated with 1:50 dilution of streptavidin prior to incubating them with
ALMS1 biotinylated antibody at 1:20 dilution overnight at RT for 1 hour to block
nonspecific binding. This was followed by incubating with 1:100 of streptavidin AlexaFluor 647 for 1 hour at RT. Finally the slides were counter-stained with DAPI at 1:2000
for 5 min at RT. For staining cilia in kidney sections, slides were incubated with 1:250
dilution of mouse anti-acetylated α-tubulin antibody (Abcam) followed by 1:200 dilution
of Alexa Fluor 488 goat anti-mouse IgG (Thermofisher) for 1 hr at RT. Slides were
mounted and imaged by Leica multi-photon microscope TCS SP8 MP (Leica
Microsystems, Germany).
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Immuno-labeling of surface NKCC2 in MDCK cells
Cells were fixed with 4% paraformaldehyde for 30 minutes at 4ºC. Fixed cells
were blocked with 5% BSA (Equitech-Bio, Kerrville, TX) in PBS (Life Technologies) for
20 minutes at RT. Anti-zonula occludens-1 (ZO-1) (1: 100 dilution) were added to the
cells for 1 hour at RT followed by (1: 100 dilution) of Alexa Fluor 568- conjugated
secondary anti-mouse antibody for 1 hour. For surface NKCC2 labeling, antibodies to
extracellular epitope of NKCC2 (1:100 dilution) [36] were added to both apical and
basolateral compartments of live cells cooled to 4ºC for 2 hours, then washed and
incubated with Alexa-Fluor 488- conjugated secondary anti-rabbit antibody for 1 hour at
4ºC in both compartments of the transwell. Cells were then fixed and labeled for ZO-1
as mentioned above. Membranes were cut and mounted on a glass slide. Glass slides
were imaged by laser scanning confocal microscopy system (Visitech International,
Sutherland, England). For z-section confocal imaging, we used an Olympus FV1200
confocal system at 60X, 1.4 NA. Z sections were obtained at 0.25µm step for 10 µm
total z-distance.
Co-immunostaining in TAL primary culture
TAL primary cells that achieved 90% confluence on permeable supports were
cooled to 4ºC. Live cells were incubated with 5 % BSA (Equitech-Bio, Kerrville, TX) in
PBS (Life Technologies) for 20 minutes at 4ºC. Surface NKCC2 was labeled with an
antibody (1:100) directed towards extracellular epitope of NKCC2 added to the apical
compartment of the live cells for 2 hours [36].

The cells were then washed and

incubated with an Alexa Fluor 488-conjugated anti-rabbit antibody for 1 hour at 4ºC in
the apical compartment of the transwell. The cells were washed and warmed to 37ºC
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for allowing internalization of the surface labeled NKCC2. The cells were then fixed with
4% paraformaldehyde for 30 min at 4ºC. Fixed cells were washed and incubated with
5% BSA in PBS for 20 min at RT. To facilitate labeling of ALMS1, biotinylated ALMS1
antibody was prepared using the antibody biotinylation kit (Pierce, Thermo Fisher
Scientific, Waltham, MA) and was then subsequently added to the apical compartment
for 1 hour at RT. The cells were washed and then incubated with streptavidin Alexa
Fluor- 647 for 1 hour at RT. The cells were then washed and a mouse primary antibody
against zonula occludens-1 (ZO-1) was added to the cells, which were incubated for 1
hour at room temperature followed by the addition of an Alexa Fluor 568-conjugated
secondary anti-mouse antibody for 1 hour. The membranes were then washed, cut and
mounted on a glass slide. Glass slides were imaged by Leica multi-photon microscope
TCS SP8 MP (Leica Microsystems, Germany). For Z-section confocal imaging, we
used this confocal system at X60, 1.4 NA. Z-sections were obtained at 0.25 µm steps
for 8.5 µm total Z-distance (35 slices). The co-localization pixels were identified by
using a Mander’s overlap coefficient ≥ 0.95.
Labeling of ALMS1 in isolated perfused rat TAL
Isolated perfused rat TALs were fixed with 4% formaldehyde and then blocked
with 2.5% BSA. We then labeled TALs with anti-ALMS1 antibody in 2.5% BSA followed
by Alexa Fluor 488 anti-rabbit IgG highly adsorbed at 1:100 in 2.5 % BSA. Images were
acquired using a laser scanning confocal microscopy system (Visitech, Sutherland,
England). Images were acquired at 100X (1.3 NA).
Blood pressure measurements
Systolic blood pressure was also measured in awake rats by tail-cuff
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plethysmography. Mean arterial pressure was measured by implanting an intra-arterial
catheter connected to a pressure transducer, into the femoral artery of rats anesthetized
with inactin i.p.
Urine and ion excretion measurements
Rats were placed in metabolic cages with free access to food and water. The
rats were allowed to get adjusted to the new cage for 3 days after which urine samples
were collected while recording body weights to ensure it remains relatively unchanged
due to any stress to the animal. Urine volume was recorded and urine osmolality was
measured by freezing point depression with Advanced Model 3300 Micro Osmometer
(Advanced Instruments Inc. Norwood, MA).

Urine Na was measured in Nova 1+

Analyzer (Nova Biomedical, Waltham, MA). For bumetanide response experiments, a
different group of rats were trained to eat all of their food between 6 P.M and 9 A.M the
next day. At 10 A.M, rats were given 1g chocolate and were trained to eat chocolate
within 10 minutes for 5 days. On day 5, urine was collected until 8 hours after the rats
were given chocolate frosting to record baseline urine volume and Na+ excretion. On
day 6, 5 mg/kg bumetanide was mixed with the chocolate pudding and urine was
collected until 8 hours after the rats were given chocolate and urine volume and Na+
excretion was measured.
Glomerular filtration rate (GFR) and renal blood flow (RBF) measurement
Rats were fasted overnight and on the following day, they were anesthetized and
their femoral vein was cannulated for bolus administration (3 µl/g body weight) of 1
mg/ml FITC-inulin followed by its constant infusion at a rate of 0.15 µl/min/g body weight
for measurement of GFR by measuring clearance of FITC-inulin. A mid line incision
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was made to expose the left kidney and the bladder. A flow probe was placed on the
renal artery to measure renal blood flow (RBF). The bladder was catheterized to collect
urine.

Plasma and urine inulin fluorescence was assessed with a Synergy H1

Microplate Reader (BioTek, Winooski, VT) to measure plasma and urine inulin
concentrations as described previously [155].
Volume expansion (VE)
Rats were anesthetized with inactin and a femoral artery and vein were
cannulated with PE-50 tubing. Femoral arterial pressure was measured with a pressure
transducer.

The bladder was exposed through a suprapubic incision and was

cannulated with a needle attached to PE-50 tubing.

Isotonic saline was infused

intravenously to administer 3 ml/100 g body weight in 30 minutes (3% volume
expansion), after which volume expansion was maintained by infusing at a rate
averaging 0.15 µl/min/g body weight.

Following a 30 minute recovery period after

surgery, urine was collected at two consecutive 30-minute intervals ((time points: 30 min
and 60 min) for baseline measurements of urine volume and urinary sodium excretion
and then at five consecutive 30-minute intervals (time points: 90 min – 210 min)
following 3% volume expansion. The data points plotted represent values for total urine
volume and urinary sodium excretion measured over 30 min starting from the preceding
data point.

These physiological parameters measured after 3% volume expansion,

were first normalized to their respective baseline values at 60 min.

Then, their

cumulative values between time points 60 min and 210 min (represented by light and
dark grey shaded regions; Figure 31A and B) were calculated and plotted in the
corresponding bar graph.
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In vivo gene silencing
The target sequence for ALMS1 silencing was a 29-nucleotide sequence from
the rat ALMS1 gene: 5’-TCCTGAATCAGGTGACCAGAAGACTCATT-3’.

The sense

and antisense sequences are spaced by a loop sequence (TCAAGAG). This shRNA
sequence was tested by transfection in NRK-52E cells. Expression of ALMS1 and
GAPDH was monitored by RT-PCR. After the efficacy of the shRNA was tested, the
shRNA was subcloned between the 5’ AscI and 3’ HindIII sites in the adenovectorpMIGHTY (Viraquest, North Liberty, IA) for production of adenoviral particles as recently
described [36].

The adenoviral ALMS1 shRNA was injected with 3 mm calibrated

needles into the outer medulla of left rat kidney while the right kidney was injected with
the control buffer acting as a sham operated kidney as described before for other genes
[156]. The kidneys were harvested 7 days later to obtain TAL suspensions which were
lysed and resolved by SDS-PAGE in 4% gels or 6% gels for the detection of ALMS1
and NKCC2 by Western blot, respectively.

Surface NKCC2 was calculated as a

percentage of total NKCC2 (sum of surface and intracellular NKCC2 fraction).
Plasma insulin and leptin measurement
Whole blood was collected from the jugular vein of rats and was immediately
mixed with appropriate volume of EDTA (5:1 ratio) to prevent blood coagulation. Blood
was then spun at 200g for 20 minutes to collect plasma. Plasma samples were used to
measure insulin and leptin concentration using Enzyme immunoassay kit from Cayman
(Ann Arbor, MI).
Plasma renin activity
Plasma renin activity was analyzed by generation of angiotensin (Ang) I (ng Ang
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I/ml/hr) using a Gamma Coat RIA kit (DiaSorin, Stillwater, MN) as previously described
and according to the manufacturer’s instructions [157].
Ingenuity pathway analysis
TAL proteins pulled down either with GST-C-ALMS1 A/B were identified by liquid
chromatography-mass spectrometry. These proteins were found to be involved with
key biological processes such as “Cellular assembly and organization”, “Molecular
transport”, “Protein trafficking”, “Renal disease” and “clathrin and caveolar-mediated
endocytosis signaling” with an enrichment probability value less than 0.05, considered
statistically significant by Ingenuity pathway network analysis (IPA: Ingenuity systems,
Inc; Qiagen, Inc.). These proteins were further curated with IPA knowledgebase by
Ingenuity pathway network analysis to determine direct or indirect interactions among
themselves.
Blood glucose and serum lipid profiling
Random and fasting blood glucose was measured using Wavesense Presto
Blood Glucose meter (AgaMatrix, Salem, NH). Lipid profiling using rat serum samples
was done using Siemen’s healthcare diagnostic analyzer (Siemens, Malvern, PA)
according to the manufacturer’s instructions.
Vascular reactivity
Briefly, rats were anesthetized with pentobarbital (50 mg/kg). Abdominal and
thoracic aorta was removed while maintaining endothelium intact and suspended in
water baths containing perfusion solution to measure phenylephrine-induced vascular
reactivity. Phenylephrine- induced vasoconstriction was measured as a percentage of
100 mM KCl-induced vascular contraction.
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Statistical analysis
Results are expressed as mean ± standard error. Single intergroup comparisons
between two groups were performed with a Student’s t-test and paired t-test for paired
samples. For Figure 27A and 30 A&B, two way analysis of variance (ANOVA) was
used to determine differences between means in two treatments and groups.

For

Figure 35, one way ANOVA was used to determine differences in means in treatments
with more than two groups.

Post hoc analysis was performed when differences

between means was found using the Bonferroni correction for multiple comparisons.
p<0.05 was considered statistically significant.
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APPENDIX A
List of acronyms
ACTN 1/4: α-actinin 1/4
ALMS1: Alström syndrome 1 protein (Italicized version correspond to its gene or RNA)
ANOVA: Analysis of Variance
ANXA2: Annexin A2
AC3: Adenylyl cyclase 3
ARF1: ADP-ribosylation factor 1
ARPC5L: Actin related protein 2/3 complex subunit 5 like
βAR: β adrenergic receptor
BAD: Biotin acceptor domain
BAT: Brown adipose tissue
BirA: Escherichia coli biotin ligase
C2-NKCC2: A region in the carboxyl-terminus of NKCC2
CKD: Chronic kidney disease
DTT: Dithiothreitol
E. coli: Escherichia coli
ENaC: Epithelial Na channel
eGFP: Enhanced green fluorescent protein
ER: Endoplasmic reticulum
FLOT2: Flotillin-2
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase
GEERC: Gene editing rat resource center
GFR: Glomerular filtration rate
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GLUT4: Glucose transporter-4
GSN: Gelsolin
GST: Glutathione S-transferase
GWAS: Genome-wide association studies
HDL: High density lipoproteins
IACUC: Institutional Animal Care and Use Committee
ILK: Integrin-linked protein kinase
IPA: Ingenuity pathway analysis
IPTG: Isopropyl β-D-1 thiogalactopyranoside
KO: Knockout
LC: Liquid chromatography
LDL: Low density lipoproteins
mRNA: messenger RNA
MAL/VIP17: Myelin and lymphocytes-associated protein
MAP: Mean arterial pressure
MDCK: Mardin Darby Canine Kidney
mIMCD3: Mouse inner medullary collecting duct
MRFIT: Multiple Risk Factor Intervention Trial
MS: Mass spectrometry
MYO5B: Myosin Vb
Na+/K+/ATPase: Sodium-potassium pump
NHE: Na/H exchanger
NHGRI: National human genome research institute
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NHS: N-Hydroxysulfosuccinimide
NIH: National Institutes of Health
NKCC2: Na+/K+/2Cl- co-transporter
NRK: Normal rat kidney
PFU: Plaque-forming unit
PHB: Prohibitin
PICALM: Phosphatidylinositol binding clathrin assembly protein
PKA: Protein kinase A
QTL: Quantitative trait loci
RAC1: Ras-related C3 botulinum toxin substrate 1
RBF: Renal blood flow
RGD: Rat genome database
RAB: Ras-related protein
RABEP1: Rabaptin
RALA: Ras-related protein Ral-A precursor
RBP: Renal blood flow
RINT1: Rad 50 interactor -1
ROMK: Renal outer medullary K+ channel
RT-PCR: Reverse transcriptase- Polymerase chain reaction
RVR: Renal vascular resistance
SBP: Systolic blood pressure
shRNA: Short hairpin RNA
SD: Sprague-Dawley
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SNP: Single nucleotide polymorphism
ss: Secretory signal
TAL: Thick ascending limb
TGF: Tubulo-glomerular feedback
TGN: Trans-golgi network
TIRF: Total internal reflection fluorescence
UMOD: Uromodulin
V2R: Vasopressin-2 receptor
WT: Wild-type
ZO-1: Zonula occludens 1
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NaCl absorption by the Thick Ascending Limb (TAL) is mediated by the apical
Na+/K+/2Cl- co-transporter, NKCC2. Increased NKCC2 activity and apical trafficking are
associated to salt sensitive hypertension in rodents and humans. NKCC2 endocytosis is
important for maintaining surface NKCC2 such that blocking NKCC2 endocytosis
increased NKCC2 surface abundance and NKCC2-mediated NaCl reabsorption.
Despite its importance, NKCC2 endocytosis has been poorly studied and a part of the
reason may be attributed to the lack of availability of methods with good time resolution.
Hence, we developed a method to image apical NKCC2 to monitor its endocytosis in
real-time by Total Internal Reflection Fluorescence (TIRF) microscopy. NKCC2
endocytosis is regulated by protein-protein interactions but only one protein has been
characterized and shown to regulate NKCC2 endocytosis by interacting with a 71 amino
acid region in the carboxyl terminus of NKCC2 (C2-NKCC2). To identify new TAL
proteins that may mediate NKCC2 endocytosis, we performed a proteomics-based
screening of TAL proteins that interacted with glutathione-S-transferase-C2-NKCC2 as
bait, and identified Alström syndrome 1 (ALMS1) as an interacting partner. ALMS1 has
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been linked to human hypertension and renal function in genome-wide association
studies, QTL in rats with salt sensitivity and mutations in the ALMS1 gene in humans
causes obesity, cardiomyopathy, type-2 diabetes, hypertension and kidney disease.
The role of ALMS1 in regulating blood pressure or renal Na+ handling is unknown. GST
pull down with C-terminus of ALMS1 (C-ALMS1) pulled down full length NKCC2 along
with several proteins known to be involved in endocytosis of other proteins. Thus, we
hypothesized that ALMS1 is involved in NKCC2 endocytosis in the TAL, NaCl
reabsorption and blood pressure regulation and generated ALMS1 knockout rat model
in collaboration with Medical College of Wisconsin. We found that in (6-12 week old)
ALMS1 KO rats, NKCC2 endocytosis was decreased and this correlated with higher
NKCC2 surface abundance in TALs. ALMS1 KO rats also exhibited higher urine
concentrating capacity, higher bumetanide sensitivity, a decreased ability to eliminate a
volume/salt load, hypertension and salt sensitivity in these rats. Altogether, this
phenotype is consistent with increased TAL function. Thus, ALMS1 interacts with
NKCC2 in the TAL, mediates its endocytosis to regulate NKCC2 surface expression and
activity in the TAL and thereby maintains normal blood pressure. In addition, ALMS1 KO
rats develop metabolic syndrome as they age (16-18 week old) and females exhibit
more severe form of metabolic dysfunction compared to their male counterparts. The
mechanism causing salt-sensitive hypertension in ALMS1 KO rats may be in part due to
higher TAL NaCl reabsorption and higher NKCC2 activity. However, it is possible that
insulin resistance and obesity that develops in these ALMS1 KO rats may play a role in
salt sensitivity. Thus, ALMS1 is not only important for renal function but may also be
involved in the regulation of glucose homeostasis and metabolism in rats.
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